PUBLICATIONS MERMAID III –Early detection, screening and long-term survival

  1. Hannibal CG, Baandrup LO, Hertzum-Larsen R, Vang R, Kurman RJ, Frederiksen K, Kjaer SK. Risk of cancer in a nationwide-based study of nearly 5,000 women with borderline ovarian tumors in Denmark. Int J Cancer 2022 (provisionally accepted May 2022) Baandrup L, Galanakis M, Hannibal CG, Dehlendorff C, Hertzum-Larsen R, Mørch LS, Kjaer SK. Long-term survival of non-localized epithelial ovarian cancer among women using menopausal hormone therapy prior to diagnosis – the Extreme study. Int J Cancer 2022 (accepted May 2022)
  1. Dareng EO, Tyrer JP, Barnes DR, Jones MR, Yang X, Aben KKH, Adank MA, et al. Polygenic risk modeling for prediction of epithelial ovarian cancer risk.. Eur J Hum Genet. 2022 Jan 14
  2. May T, Bernardini M, Lheureux S, Johnatty S, AOCS Group, Webb PM, Friedlander M, Chenevix-Trench G et al. Clinical Parameters Affecting Survival Outcomes in Women with Low-Grade Serous Ovarian Carcinoma: An International Multicenter Analysis. Canadian Journal of Surgery. 2021 May 25
  3. Yang X, Song H, Leslie G, Engel C, Hahnen E, Auber B, Horváth J, Kast K, Niederacher D, Turnbull C, Houlston R, Hanson H, Loveday C, Dolinsky JS, LaDuca H, Ramus SJ, Menon U, Rosenthal AN, Jacobs I, Gayther SA, Dicks E, Nevanlinna H, Aittomäki K, Pelttari LM, Ehrencrona H, Borg Å, Kvist A, Rivera B, Hansen TVO, Djursby M, Lee A, Dennis J, Bowtell DD, Traficante N, Diez O, Balmaña J, Gruber SB, Chenevix-Trench G; kConFab Investigators, Jensen A, Kjær SK, Høgdall E, Castéra L, Garber J, Janavicius R, Osorio A, Golmard L, Vega A, Couch FJ, Robson M, Gronwald J, Domchek SM, Culver JO, de la Hoya M, Easton DF, Foulkes WD, Tischkowitz M, Meindl A, Schmutzler RK, Pharoah PDP, Antoniou AC. Ovarian and breast cancer risks associated with pathogenic variants in RAD51C and RAD51D. J Natl Cancer Inst. 2020 Feb 28
  4. Lee AW, Wu AH, Wiensch A, Mukherjee B, Terry KL, Harris HR, Carney ME, Jensen A, Cramer DW, Berchuck A, Doherty JA, Modugno F, Goodman MT, Alimujiang A, Rossing MA, Cushing-Haugen KL, Bandera EV, Thompson PJ, Kjaer SK, Hogdall E, Webb PM, Huntsman DG, Moysich KB, Lurie G, Ness RB, Stram DO, Roman L, Pike MC, Pearce CL; Ovarian Cancer Association Consortium. Estrogen plus progestin hormone therapy and ovarian cancer: a complicated relationship explored. 2020 Feb 4.
  5. Outcomes in Women with Low-Grade Serous Ovarian Carcinoma: An International Multicenter Analysis. Canadian Journal of Surgery. 2021 May 25
  6. Song H, Dicks EM, Tyrer J, Intermaggio M, Chenevix-Trench G, Bowtell DD, et al. Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer. J Med Genet. 2021 May;58(5):305-313.
  7. Glubb DM, Thompson DJ, Aben KKH, Alsulimani A, Amant F, Annibali D et al,. Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Cancer Epidemiol Biomarkers Prev. 2021 Jan;30(1):217-228.
  8. Kar SP, Considine DPC, Tyrer JP, Plummer JT, Chen S, Dezem FS, Barbeira AN et al. Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer.HGG Adv. 2021 Jul 8;2(3):100042.
  9. Quinn MCJ, McCue K, Shi W, Johnatty SE, Beesley J, Civitarese A, O’Mara TA, et al. Identification of a Locus Near ULK1 Associated With Progression-Free Survival in Ovarian Cancer. Cancer Epidemiol Biomarkers Prev. 2021 Jun 23. doi: 10.1158/1055-9965.EPI-20-1817. Online ahead of print
  1. Gottschau M, Aalborg GL, Settnes A, Viuff JH, Munk C, Jensen A, Krüger SK, Mellemkjær L. Bilateral salpingo-oophorectomy at benign hysterectomy and long term health consequences in pre- and postmenopausal women – A Danish nationwide cohort study. BMJ 2022 (submitted February 2022)
  1. Baandrup L, Dehlendorff C, Hertzum-Larsen R, Hannibal CG, Kjaer SK. Prognostic impact of socioeconomic status on long-term survival of non-localized epithelial ovarian cancer The Extreme study. Gynecol Oncol. 2021 Feb 11:S0090-8258(21)00102-5.
  2. Faber MT, Horsbøl TA, Baandrup LO, Dalton SO, Kjaer SK. Trends in survival of ovarian cancer by histology and socioeconomic status in Denmark 1996-2017.  Gynecol Oncol. 2021 Nov 8:S0090-8258(21)01554-7
  3. Urbute A, Frederiksen K, Kjaer SK. Early adulthood overweight and obesity and risk of premenopausal ovarian cancer, and premenopausal breast cancer including receptor status: prospective cohort study of nearly 500,000 Danish women.. Ann Epidemiol. 2022 Jun;70:61-67
  4. Khoja L, Weber RP; Australian Ovarian Cancer Study Group, Webb PM, Jordan SJ, Muthukumar A, Chang-Claude J, Fortner RT, Jensen A, Kjaer SK, Risch H, Doherty JA, Harris HR, Goodman MT, Modugno F, Moysich K, Berchuck A, Schildkraut JM, Cramer D, Terry KL, Anton-Culver H, Ziogas A, Phung MT, Hanley GE, Wu AH, Mukherjee B, McLean K, Cho K, Pike MC, Pearce CL, Lee AW. Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association. Gynecol Oncol. 2021 Nov 11:S0090-8258(21)01552-3
  1. Baandrup L, Faber MT, Aalborg GL, Kjaer SK. Borderline ovarian tumors in Denmark 1997-2018: Time trends in incidence by histology, age and educational level. Acta Obstet Gynecol Scand. 2021 Mar;100(3):436-443
  2. Chui MH, Kjaer SK, Frederiksen K, Hannibal CG, Wang TL, Vang R, Shih IM. BRAF(V600E) -mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma. Correction. Oncotarget. 2021 Jun 22;12(13):1323-1324.
  3. Ørnskov D, Waldstrøm M, Thomsen LT, Munk C, Kjaer SK. A Danish Clinical Cervical Cytology Biobank. Processing and quality of biobanked samples. Biopreservation & Biobanking 2022 Jul 13.
  4. Hemmingsen CH, Kjaer SK, Bennetsen AKK, Dehlendorff C, Baandrup L. Risk factors for non-epithelial ovarian cancer. Gynecol Oncol. 2021 Aug;162(2):469-474 Bennetsen AKK, Baandrup L, Aalborg GL, Kjaer SK. Non-epithelial ovarian cancer in Denmark – incidence and survival over nearly 40 years. Gynecol Oncol 2020 Jun;157(3):693-699
  1. Brieger KK, Peterson S, Lee AW, Mukherjee B, Bakulski KM, Alimujiang A et al. Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved surviva.  Gynecol Oncol. 2020 Jul 5:S0090-8258(20)32296-4. doi: 10.1016/j.ygyno.2020.06.481. Online ahead of print.PMID: 32641237
  2. Gottschau M, Kjær SK, Settnes A, Aalborg GL, Bens A, Jensen A, Munk C, Mellemkjær L. Ovarian removal at or after benign hysterectomy and breast cancer: a nationwide cohort study. Breast Cancer Research and Treatment 2020; 181:475–485
  3. Hannibal CG, Frederiksen K, Vang R, Kurman RJ, Kjær SK. Risk of specific types of ovarian cancer after ovarian borderline tumors in Denmark: a population-based study. Int J Cancer. 2020 Aug 15;147(4):990-995
  4. Guleria S, Jensen A, Tønder A, Kjaer SK. Risk of epithelial ovarian cancer among women with benign ovarian tumors: a follow-up study. Cancer Causes Control Cancer Causes Control. 2020;31(1):25-31.
  5. Reinholdt K, Kjaer SK, Guleria S, Frederiksen K, Mellemkjær L, Munk C, Jensen A. Benign ovarian tumors and risk of endometrial cancer: a Danish nationwide cohort study.                                    Gynecol Oncol. 2020 May; 157(2): 549-554.
  6. Lee AW, Wu AH, Wiensch A, Mukherjee B, Terry KL, Harris HR, Carney ME, Jensen A, Cramer DW, Berchuck A, Doherty JA, Modugno F, Goodman MT, Alimujiang A, Rossing MA, Cushing-Haugen KL, Bandera EV, Thompson PJ, Kjaer SK, Hogdall E, Webb PM, Huntsman DG, Moysich KB, Lurie G, Ness RB, Stram DO, Roman L, Pike MC, Pearce CL; Ovarian Cancer Association Consortium. Estrogen plus progestin hormone therapy and ovarian cancer: a complicated relationship explored. Epidemiology. 2020 May;31(3):402-40
  7. Horsboel TA, Dalton SO, Ammitzbøll G, Johansen C, Andersen EAW, Jensen PT, Frøding LP, Lajer H, Kjær SK. Gynecological cancer leads to long-term sick leave and permanently reduced working ability years after diagnosis. J of Cancer Survivorship 2020 Dec;14(6):867
  8. Hannibal CG, Frederiksen K, Vang R, Kurman R, Kjær SK. Hannibal CG, Frederiksen K, Vang R, Kurman RJ, Kjær SK. Risk of specific types of ovarian cancer after ovarian borderline tumors in Denmark: a population-based study. Int J Cancer. 2020 Aug 15;147(4):990-995
  9. Verdoodt F, Dehlendorff C, Jäättelä M, Strauss R, Pottegård A, Hallas J, Friis S, Kjaer SK. Antihistamines and ovarian cancer survival: nationwide cohort study and in vitro cell viability assay. J Natl Cancer Inst. 2019 Nov 5. pii: djz217
  10. Harris HR, Cushing-Haugen KL, Webb PM, Nagle CM, Jordan SJ; Australian Ovarian Cancer Study Group, Risch HA, Rossing MA, Doherty JA, Goodman MT, Modugno F, Ness RB, Moysich KB, Kjær SK, Høgdall E, Jensen A, Schildkraut JM, Berchuck A, Cramer DW, Bandera EV, Rodriguez L, Wentzensen N, Kotsopoulos J, Narod SA, McLaughlin JR, Anton-Culver H, Ziogas A, Pearce CL, Wu AH, Lindström S, Terry KL. Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study. Int J Epidemiol. 2019 Jun 1;48(3):822-830
  11. Jiang X, Finucane HK, Schumacher FR, Schmit SL, Tyrer JP, Han Y, Michailidou K, et al. Shared heritability and functional enrichment across six solid cancers. Nat Commun. 2019 Jan 25;10(1):431
  12. Kim S, Wang M, Tyrer JP, Jensen A, Wiensch A, Liu G, Lee AW, Ness RB, Salvatore M, Tworoger SS, Whittemore AS, Anton-Culver H, Sieh W, Olson SH, Berchuck A, Goode EL, Goodman MT, Doherty JA, Chenevix-Trench G, Rossing MA, Webb PM, Giles GG, Terry KL, Ziogas A, Fortner RT, Menon U, Gayther SA, Wu AH, Song H, Brooks-Wilson A, Bandera EV, Cook LS, Cramer DW, Milne RL, Winham SJ, Kjaer SK, Modugno F, Thompson PJ, Chang-Claude J, Harris HR, Schildkraut JM, Le ND, Wentzensen N, Trabert B, Høgdall E, Huntsman D, Pike MC, Pharoah PDP, Pearce CL, Mukherjee B. A comprehensive gene-environment interaction analysis in Ovarian Cancer using genome-wide significant common variants. Int J Cancer. 2019 May 1;144(9):2192-2205
  13. Chui MH, Kjaer SK, Frederiksen K, Hannibal CG, Wang T-L, Vang R, Shih I-M.BRAFV600E-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma. Oncotarget 2019 Dec 3;10(64):6870-6878
  14. Minlikeeva AN, Cannioto R, Jensen A, Kjaer SK, Jordan SJ, Diergaarde B, Szender JB, Odunsi K, Almohanna H, Mayor P, Starbuck K, Zsiros E, Bandera EV, Cramer DW, Doherty JA, DeFazio A; Australian Ovarian Cancer Study Group, Edwards R, Goode EL, Goodman MT, Høgdall E, Matsuo K, Mizuno M, Nagle CM, Ness RB, Paddock LE, Pearce CL, Risch HA, Rossing MA, Terry KL, Wu AH, Modugno F, Webb PM, Moysich KB; Ovarian Cancer Association Consortium. Joint exposure to smoking, excessive weight, and physical inactivity and survival of ovarian cancer patients, evidence from the Ovarian Cancer Association Consortium. Cancer Causes Control.2019;30:537-47
  15. Horsbøl TA, Kjær SK, Johansen C, Suppli NP, Ammitzbøll G, Frøding LP, Lajer H, Dalton SO. Increased risk for depression persists for years among women treated for gynaecological cancers. A register-based cohort study with up to 19 years of follow-up. Gynecologic Oncology 2019 Jun;153(3):625-632
  16. Chui MH, Xing D, Zeppernick F, Wang ZQ, Hannibal CG, Frederiksen K, Kjaer SK, Cope L, Kurman RJ, Shih IM, Wang TL, Vang R. Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma. Am J Surg Pathol. 2019 Nov;43(11):1462-1472.
  17. Verdoodt A, Pottegård A, Dehlendorff C, Jäättela M, Hallas J, Friis S, Kjær SK. Antihistamine use and risk of ovarian cancer: a population-based case-control study. Maturitas. 2019 ;120:47-52
  18. Harris HR, Cushing-Haugen KL, Webb PM, Nagle CM, Jordan SJ; Australian Ovarian Cancer Study Group, Risch HA, Rossing MA, Doherty JA, Goodman MT, Modugno F, Ness RB, Moysich KB, Kjær SK, Høgdall E, Jensen A, Schildkraut JM, Berchuck A, Cramer DW, Bandera EV, Rodriguez L, Wentzensen N, Kotsopoulos J, Narod SA, McLaughlin JR, Anton-Culver H, Ziogas A, Pearce CL, Wu AH, Lindström S, Terry KL. Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study. Int J Epidemiol. 2019 Jun 1;48(3):822-830
  19. Rask L, Høgdall CK, Kjaer SK, Christensen L, Jensen A, Blaakaer J, Christensen IJ, Høgdall EVS. Association of CD31 and p53 With Survival of Ovarian Cancer Patients. Anticancer Res. 2019 Feb;39(2):567-576.
  20. Gottschau M, Jensen A, Reinholdt K, Guleria S, Munk C, Mellemkjær L, Kjær SK. Risk of breast cancer among women with benign ovarian tumors: a Danish nationwide cohort study. Breast Cancer Res Treat. 2019 Nov;178(1):199-205
  21. Verdoodt F, Kjaer SK, Dehlendorff C, Friis S. Aspirin use and ovarian cancer mortality in a Danish nationwide cohort study. Br J Cancer. 2018 Feb 20;118(4):611-615
  22. Babic A, Harris HR, Vitonis AF, Titus LJ, Jordan SJ, Webb PM; Australian Ovarian Cancer Study Group, Risch HA, Rossing MA, Doherty JA, Wicklund K, Goodman MT, Modugno F, Moysich KB, Ness RB, Kjaer SK, Schildkraut J, Berchuck A, Pearce CL, Wu AH, Cramer DW, Terry KL. Menstrual pain and risk of epithelial ovarian cancer: Results from the Ovarian Cancer Association Consortium. Int J Cancer. 2018;142(3):460-469
  23. Ong JS, Hwang LD, Cuellar-Partida G, Martin NG, Chenevix-Trench G, Quinn MCJ et al. Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol. 2018 Apr 1;47(2):450-459. doi: 10.1093/ije/dyx236.
  24. Kelemen LE, Earp M, Fridley BL, Chenevix-Trench G; Australian Ovarian Cancer Study Group, Fasching PA, Beckmann MW et al. rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. Int J Mol Sci. 2018 Aug 21;19(9)
  25. Kim S, Wang M, Tyrer JP, Jensen A, Wiensch A, Liu G, et al. A Comprehensive Gene-Environment Interaction Analysis in Ovarian Cancer using Genome-wide Significant Common Variants. Int J Cancer. 2018 Nov 29
  26. Dixon-Suen SC, Nagle CM, Thrift AP, Pharoah PDP, Ewing A, Pearce CL et al. Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. Br J Cancer. 2018 Apr;118(8):1123-1129.
  27. Lu Y, Beeghly-Fadiel A, Wu L, Guo X, Li B, Schildkraut JM et al. A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res. 2018 Sep 15;78(18):5419-5430
  28. Rambau PF, Vierkant RA, Intermaggio MP, Kelemen LE, Goodman MT, Herpel E et al. Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. J Pathol Clin Res. 2018 Jul 30
  29. Block MS, Vierkant RA, Rambau PF, Winham SJ, Wagner P, Traficante N et al. MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc. 2018 Mar;93(3):307-320.
  30. Earp M, Tyrer JP, Winham SJ, Lin HY, Chornokur G, Dennis J et al. Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. PLoS One. 2018 Jul 6;13(7):e0197561.
  31. Harris HR, Babic A, Webb PM, Nagle CM, Jordan SJ, Risch HA et al. Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev. 2018 Feb;27(2):174-182.
  32. Verdoodt F, Dehlendorff C, Friis S, Kjaer SK. Non-aspirin NSAID use and ovarian cancer mortality. Gynecol Oncol. 2018 Aug;150(2):331-337
  33. Pottegård A, Friis S, Verdoodt A, Dehlendorff C, Hallas J, Kjær SK. Use of prescription drugs among ovarian cancer patients in Denmark. Acta Obstet Gynecol Scand. 2018;97(11):1332-1338
  34. Wang Y, Li L, Douville C, Cohen JD, Yen TT, Kinde I, Sundfelt K, Kjær SK, Hruban RH, Shih IM, Wang TL, Kurman RJ, Springer S, Ptak J, Popoli M, Schaefer J, Silliman N, Dobbyn L, Tanner EJ, Angarita A, Lycke M, Jochumsen K, Afsari B, Danilova L, Levine DA, Jardon K, Zeng X, Arseneau J, Fu L, Diaz LA Jr, Karchin R, Tomasetti C, Kinzler KW, Vogelstein B, Fader AN, Gilbert L, Papadopoulos N. Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. Sci Transl Med. 2018 Mar 21;10(433).
  35. Liu G, Mukherjee B, Lee S, Lee AW, Wu AH, Bandera EV, Jensen A, Rossing MA, Moysich KB, Chang-Claude J, Doherty JA, Gentry-Maharaj A, Kiemeney L, Gayther SA, Modugno F, Massuger L, Goode EL, Fridley BL, Terry KL, Cramer DW, Ramus SJ, Anton-Culver H, Ziogas A, Tyrer JP, Schildkraut JM, Kjaer SK, Webb PM, Ness RB, Menon U, Berchuck A, Pharoah PD, Risch H, Pearce CL; Ovarian Cancer Association Consortium. Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. Am J Epidemiol. 2018 Feb 1;187(2):366-377
  36. Epidemiology Working Group Steering Committee, Ovarian Cancer Association Consortium Members of the EWG SC, in alphabetical order:, Doherty JA, Jensen A, Kelemen LE, Pearce CL, Poole E, Schildkraut JM, Terry KL, Tworoger SS, Webb PM, Wentzensen N. Current Gaps in Ovarian Cancer Epidemiology: The Need for New Population-Based Research. J Natl Cancer Inst. 2018 Oct 1;109(10)
  37. Hannibal CG, Dehlendorff C, Kjaer SK. Use of paracetamol, low-dose aspirin, or non-aspirin non-steroidal anti-inflammatory drugs and risk of ovarian borderline tumors in Denmark. Gynecol Oncol. 2018 Sep 21. pii: S0090-8258(18)31242-3.
  38. Hannibal CG, Vang R, Junge J, Frederiksen K, Kurman RJ, Kjaer SK. A nationwide study of ovarian serous borderline tumors in Denmark 1978-2002. Risk of recurrence, and development of ovarian serous carcinoma. Gynecol Oncol. 2017 Jan;144(1):174-180
  39. Sucheston-Campbell LE, Cannioto R, Clay AI, Etter JL, Eng KH, Liu S et al. No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. Cancer Epidemiol Biomarkers Prev. 2017 Mar;26(3):420-424
  40. Minlikeeva AN, Freudenheim JL, Eng KH, Cannioto RA, Friel G, Szender JB et al. History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev. 2017 Sep;26(9):1470-1473
  41. Minlikeeva AN, Freudenheim JL, Cannioto RA, Eng KH, Szender JB, Mayor Pet al. History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report. Br J Cancer. 2017 Aug 17.
  42. Dixon SC, Nagle CM, Wentzensen N, Trabert B, Beeghly-Fadiel A, Schildkraut JM, Moysich KB et al. Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. Br J Cancer. 2017 Apr 25;116(9):1223-1228.
  43. Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, Lawrenson K, Winham SJ et al. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet. 2017 May;49(5):680-691
  44. Minlikeeva AN, Freudenheim JL, Cannioto RA, Szender JB, Eng KH, Modugno F et al. History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium. Cancer Causes Control. 2017 May;28(5):469-486.
  45. Glubb DM, Johnatty SE, Quinn MCJ, O’Mara TA, Tyrer JP, Gao B et al Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci. Oncotarget. 2017 Jun 15;8(39):64670-64684.
  46. Rasmussen ELK, Hannibal CG, Dehlendorff C, Baandrup L, Junge J, Vang R, Kurman RJ, Kjaer SK. Parity, infertility, oral contraceptives, and hormone replacement therapy and the risk of ovarian serous borderline tumors: a nationwide case-control study. Gynecol Oncol. 2017 Mar;144(3):571-576s).
  47. Kar SP, Adler E, Tyrer J, Hazelett D, Anton-Culver H, Bandera EV, Beckmann MW et al Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. Br J Cancer. 2017 Feb 14;116(4):524-535.
  48. Verdoodt F, Kjaer Hansen M, Kjaer SK, Pottegård A, Friis S, Dehlendorff C. Statin use and mortality among ovarian cancer patients: a population-based cohort study. Int J Cancer 2017 Jul 15;141(2):279-286
  49. Minlikeeva AN, Freudenheim JL, Eng KH, Cannioto RA, et al. History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev. 2017 Sep;26(9).
  50. Vang R, Hannibal CG, Junge J, Frederiksen K, Kjaer SK, Kurman RJ. Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases. Am J Surg Pathol. 2017 Jun;41(6):725-737.
  51. Verdoodt F, Kjaer SK, Friis S. Influence of aspirin and non-aspirin NSAID use on ovarian and endometrial cancer: Summary of epidemiologic evidence of cancer risk and prognosis. Maturitas. 2017 Jun;100:1-7.
  52. Verdoodt F, Friis S, Dehlendorff C, Albieri V, Kjaer SK. Response to comment from Brasky et al. Gynecol Oncol Rep. 2016 Oct 27;18:59. eCollection 2016 Nov
  53. Mørch LS, Dehlendorff C, Baandrup L, Friis S, Kjaer SK. Use of antidepressants and risk of epithelial ovarian cancer. Int J Cancer. 2017 Dec 1;141(11):2197-2203.
  54. Præstegaard C, Jensen A, Jensen SM, Nielsen TS et al. Cigarette smoking is associated with adverse survival among women with ovarian cancer: results from a pooled analysis of 20 studies Int J Cancer. 2017 Jun 1;140:2422-2435.
  55. Xing D, Rahmanto YS, Zeppernick F, Hannibal CG, Kjaer SK, Vang R, Shih IM, Wang TL. Mutation of NRAS is a Rare Genetic Event in Ovarian Low-Grade Serous Carcinoma. Hum Pathol. 2017 Sep 2. pii: S0046-8177(17)30303-9
  56. Guleria S, Jensen A, Kjær SK. Risk of borderline ovarian tumors among women with benign ovarian tumors: A cohort study. Gynecol Oncol. 2017 Nov 23. pii: S0090-8258(17)31534-2.
  57. Rasmussen CB, Jensen A, Albieri V, Andersen KK, Kjaer SK. Is pelvic inflammatory disease a risk factor for ovarian cancer? Cancer Epidemiol Biomarkers Prev. 2017; 26(1); 104-109
  58. Rasmussen CB, Kjaer SK, Albieri V, Bandera EV, Doherty JA, Høgdall E, Webb PM, Jordan SJ, AOCS Study Group, Rossing MA, Wicklund KG, Goodman MT, Modugno F, Moysich KB, Ness RB, Edwards RP, Schildkraut JM,  Berchuck A, Olson SH, Kiemeney LA, Massuger LFAG, Narod SA, Phelan C, Anton-Culver H, Ziogas A, Wu AH, Pearce CL, Risch HA, Jensen A on behalf of the Ovarian Cancer Association Consortium. Pelvic Inflammatory Disease and Risk of Ovarian Cancer and Borderline Ovarian Tumors: A Pooled Analysis of 13 Case-Control Studies. Am J Epidemiology. 2017; 185(1): 8-20
  59. Permuth JB, Pirie A, Chen YA, Lin HY, Reid BM, Chen Z, Monteiro A et al. Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk. Hum Mol Genet. 2016 Aug 15;25(16):3600-3612
  60. Kar SP, Beesley J, Amin Al Olama A, Michailidou K, Tyrer J, Kote-Jarai Z, Lawrenson K et al. Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discov. 2016 Sep;6(9):1052-67.
  61. Permuth JB, Reid B, Earp M, Chen YA, Monteiro AN, Chen Z et al. Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. Oncotarget. 2016 Nov 8;7(45):72381-72394.
  62. Hampras SS, Sucheston-Campbell LE, Cannioto R, Chang-Claude J, Modugno F, Dörk T et al. Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget. 2016 Oct 25;7(43):69097-69110
  63. Usset JL, Raghavan R, Tyrer JP, McGuire V, Sieh W, Webb P et al. Assessment of multifactor gene-environment interactions and ovarian cancer risk: candidate genes, obesity, and hormone-related risk factors. Cancer Epidemiol Biomarkers Prev. 2016 May;25(5):780-90.
  64. Lee AW, Ness RB, Roman LD, Terry KL, Schildkraut JM, Chang-Claude J et al. Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk. Obstet Gynecol. 2016 May;127(5):828-36.
  65. Lee AW, Bomkamp A, Bandera EV, Jensen A, Ramus SJ, Goodman MT et al. A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer. Int J Cancer. 2016. (139) 2646-2654.Cuellar-Partida G, Lu Y, Dixon SC; Australian Ovarian Cancer Study, Fasching PA, Hein A et al. Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Hum Genet. 2016 Jul;135(7):741-56.
  66. Cannioto R, LaMonte MJ, Risch HA, Hong CC, Sucheston-Campbell LE, Eng KH et al. Chronic Recreational Physical Inactivity and Epithelial Ovarian Cancer Risk: Evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1114-24.
  67. Wang Y, Bernhardy AJ, Cruz C, Krais JJ, Nacson J, Nicolas E et al. The BRCA1-?11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin. Cancer Res. 2016 May 1;76(9):2778-90.
  68. Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, Sher T et al. Corrigendum: Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet. 2016 Jan;48(1):101.
  69. Meeks HD, Song H, Michailidou K, Bolla MK, Dennis J, Wang Q et al.BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. J Natl Cancer Inst. 2016 Feb; 108(2): djv315.
  70. Rasmussen CB, Jensen A, Albieri V, Andersen KK, Kjaer SK. Increased risk of borderline ovarian tumors in women with a history of pelvic inflammatory disease: A nationwide population-based cohort study. Gynecol Oncol. 2016 Nov;143(2):346-351. doi: 10.1016/j.ygyno.2016.08.318.
  71. Gottschau M, Mellemkjaer L, Hannibal CG, Kjaer SK. Ovarian and tubal cancer in Denmark: an update on incidence and survival. Acta Obstet Gynecol Scand. 2016 Oct;95(10):1181-9.
  72. Mogensen JB, Kjær SK, Mellemkjær L, Jensen A. Endometriosis and risks for ovarian, endometrial and breast cancers: A nationwide cohort study. Gynecol Oncol. 2016 Oct;143(1):87-92.
  73. Nagle CM, Dixon SC, Jensen A, Kjaer SK, Modugno F, deFazio A et al. Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium. Br J Cancer. 2015 Sep 1;113(5):817-26.
  74. Gottschau M, Kjaer SK, Jensen A, Munk C, Mellemkjaer L. Risk of cancer among women with polycystic ovary syndrome: a Danish cohort study. Gynecol Oncol. 2015 Jan;136(1):99-103.
  75. Præstegaard C, Jensen SM, Kjaer SK, Nielsen TS, Webb PM, Nagle CM et al. The association between socioeconomic status and ovarian cancer survival: a pooled analysis of 18 studies. Cancer Epidemiol. 2016 Apr;41:71-9
  76. Ibfelt EH, Dalton SO, Høgdall C, Fagö-Olsen CL, Steding-Jessen M, Osler M, Johansen C, Frederiksen K, Kjær SK. Do stage of disease, comorbidity or access to treatment explain socioeconomic differences in survival after ovarian cancer? – A cohort study among Danish women diagnosed 2005-2010. Cancer Epidemiol. 2015;39(3):353-9.
  77. Lee AW, Tyrer JP, Doherty JA, Stram DA, Kupryjanczyk J, Dansonka-Mieszkowska Aet al. Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study. Gynecol Oncol. 2015 Mar;136(3):542-8.
  78. Kuchenbaecker KB, Ramus SJ, Tyrer J, Lee A, Shen HC, Beesley J et al. Identification of six new susceptibility loci for invasive epithelial ovarian cancer.  Nat Genet. 2015 Feb;47(2):164-71
  79. Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2, Hollestelle A, van der Baan FH, Berchuck A, Johnatty SE, Aben KK, Agnarsson BAet al. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol. 2015 May 2. pii: S0090-8258(15)00863-X.
  80. Chornokur G, Lin HY, Tyrer JP, Lawrenson K, Dennis J, Amankwah EK, Qu Xet al. Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. PLoS One. 2015 Jun 19;10(6):e0128106.
  81. Ovarian Cancer Association Consortium; Australian Cancer Study; Australian Ovarian Cancer Study Group. Genome-wide significant risk associations for mucinous ovarian carcinoma. Nat Genet. 2015;47(8):888-97.
  82. Song H, Dicks E, Ramus SJ, Tyrer JP, Intermaggio MP, Hayward J, Edlund CKet al. Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population. J Clin Oncol. 2015 Sep 10;33(26):2901-7
  83. Lu Y, Cuellar-Partida G, Painter JN, Nyholt DR; Australian Ovarian Cancer Study; International Endogene Consortium (IEC), Morris AP, Fasching PAet al. Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. Hum Mol Genet. 2015 Oct 15;24(20):5955-64.
  84. Amankwah EK, Lin HY, Tyrer JP, Lawrenson K, Dennis J, Chornokur G, Aben KK et al. Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genet Epidemiol. 2015 Dec;39(8):689-97
  85. Johnatty S, Tyrer JP, Kar SP, Beesley J, Lu Y, Gao B, Fasching PAet al. Genome-wide analysis identifies novel loci associated with ovarian cancer outcomes: findings from the Ovarian Cancer Association Consortium. Clin Cancer Res. 2015 Dec 1;21(23):5264-76
  86. Lawrenson K, Li Q, Kar S, Seo JH, Tyrer J, Spindler TJ, Lee J et al. Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nat Commun. 2015 Sep 22;6:8234.
  87. Kar SP, Tyrer JP, Li Q, Lawrenson K, Aben KK, Anton-Culver H et al. Network-based integration of GWAS and gene expression identifies a HOX-centric network associated with serous ovarian cancer risk. Cancer Epidemiol Biomarkers Prev. 2015 Oct;24(10):1574-84
  88. Lawrenson K, Iversen ES, Tyrer J, Weber RP, Concannon P, Hazelett DJ et al. Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. Carcinogenesis. 2015 Nov;36(11):1341-53.
  89. Lee AW, Templeman C, Stram DA, Beesley J, Tyrer J, Berchuck A, Pharoah PP, Chenevix-Trench G, Pearce CL; Ovarian Cancer Association Consortium. Evidence of a genetic link between endometriosis and ovarian cancer. Fertil Steril. 2016 Jan;105(1):35-43.e10.
  90. Jim HS, Lin HY, Tyrer JP, Lawrenson K, Dennis J, Chornokur Get al. Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). J Genet Genome Res. 2015;2(2).
  91. Winham SJ, Pirie A, Chen YA, Larson MC, Fogarty ZC, Earp MA et al. Investigation of exomic variants associated with overall survival in ovarian cancer. Cancer Epidemiol Cancer Epidemiol Biomarkers Prev. 2016 Mar;25(3):446-54
  92. Coetzee SG, Shen HC, Hazelett DJ, Lawrenson K, Kuchenbaecker K, Tyrer J, Ovarian Cancer Association Consortium The Consortium of Investigators of Modifiers of BRCA1/2. Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. Hum Mol Genet. 2015 Jul 1;24(13):3595-607.
  93. French JD, Johnatty SE, Lu Y, Beesley J, Gao B, Kalimutho M, Henderson MJet al. Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer. Oncotarget. 2016 Feb 9;7(6):6353-68
  94. Kelemen LE, Lawrenson K, Tyrer J, Li Q, Lee JM, Seo JH, Phelan CM, Beesley J, Chen X, Spindler TJ, Aben KK, Anton-Culver H, Antonenkova N; Australian Cancer Study; Australian Ovarian Cancer Study Group; Ovarian Cancer Association Consortium. Genome-wide significant risk associations for mucinous ovarian carcinoma. Nat Genet. 2015 Aug;47(8):888-97.
  95. Zeppernick F, Ardighieri L, Hannibal CG, Vang R, Junge J, Kjaer SK, Zhang R, Kurman RJ, Shih IeM. BRAF mutation is associated with a specific cell type with features suggestive of senescence in ovarian serous borderline (atypical proliferative) tumors. Am J Surg Pathol. 2014;38(12):1603-11.
  96. Hannibal CG, Vang R, Junge J, Frederiksen K, Kjaerbye-Thygesen A, Andersen KK, Tabor A, Kurman RJ, Kjaer SK. A nationwide study of serous “borderline” ovarian tumors in Denmark 1978-2002: centralized pathology review and overall survival compared with the general population. Gynecol Oncol. 2014 Aug;134(2):267-73.
  97. Collaborative Group On Epidemiological Studies Of Ovarian Cancer. Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, Peto R. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet. 2015 May 9;385(9980):1835-42
  98. Gosvig CF, Kjaer SK, Blaakær J, Høgdall E, Høgdall C, Jensen A. Coffee, tea, and caffeine consumption and risk of epithelial ovarian cancer and borderline ovarian tumors: Results from a Danish case-control study. Acta Oncol. 2015;54(8):1144-51.
  99. Baandrup L, Kjaer SK, Olsen JH, Dehlendorff C, Friis S. Low-dose aspirin use and the risk of ovarian cancer in Denmark. Ann Oncol. 2015 Apr;26(4):787-92.
  100. Baandrup L, Dehlendorff C, Friis S, Olsen JH, Kjær SK. Statin use and risk for ovarian cancer: a Danish nationwide case-control study. Br J Cancer. 2015 Jan 6;112(1):157-61.
  101. Bjørnholt SM, Kjaer SK, Nielsen TS, Jensen A. Risk for borderline ovarian tumours after exposure to fertility drugs: results of a population-based cohort study. Hum Reprod. 2015 Jan;30(1):222-31.
  102. Madsen C, Baandrup L, Dehlendorff C, Kjaer SK. Tubal ligation and salpingectomy and the risk of epithelial ovarian cancer and borderline ovarian tumors: a nationwide case-control study. Acta Obstet Gynecol Scand. 2015 Jan;94(1):86-94.

PUBLICATIONS MERMAID III – Biomarkers and/or Prognostic markers

OVERVIEW OF PUBLICATIONS (start of MERMAID IIIC project – March 2020)

The publications only include publications based on data or biological specimens collected under the MERMAID connected Pelvic Mass III or GOVEC studies.

  1. Lopacinska-Jørgensen, J.; Oliveira, D.V.N.P.; Høgdall, C.K.; Høgdall, E.V. Identification of stably expressed reference microRNAs in epithelial ovarian cancer. Accepted PIIAR In Vivo, March 2022.
  2. Vergote, I.; Gonzalez-Martin, A.; Ray-Coquard, I.; Harter, P.; Colombo, N.; Pujol, P.; Lorusso, D.; Mirza, M.R.; Brasiuniene, B.; Madry, R.; et al. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer. Ann Oncol 2022, 33, 276-287, doi:10.1016/j.annonc.2021.11.013.
  3. Sørensen, S.M.; Høgdall, C.; Mosgaard, B.J.; Dalgaard, M.I.R.; Jensen, M.P.; Fuglsang, K.; Schnack, T.H. Residual tumor and primary debulking surgery vs interval debulking surgery in stage IV epithelial ovarian cancer. Acta Obstet Gynecol Scand 2022, 101, 334-343, doi:10.1111/aogs.14319.
  4. Sisman, Y.; Schnack, T.; Hogdall, E.; Hogdall, C. Organoids and epithelial ovarian cancer – a future tool for personalized treatment decisions? (Review). Mol Clin Oncol 2022, 16, 29, doi:10.3892/mco.2021.2462.
  5. Ekmann-Gade, A.W.; Hogdall, C.K.; Seibaek, L.; Noer, M.C.; Fago-Olsen, C.L.; Schnack, T.H. Incidence, treatment, and survival trends in older versus younger women with epithelial ovarian cancer from 2005 to 2018: A nationwide Danish study. Gynecol Oncol 2022, 164, 120-128, doi:10.1016/j.ygyno.2021.10.081.
  6. Dareng, E.O.; Tyrer, J.P.; Barnes, D.R.; Jones, M.R.; Yang, X.; Aben, K.K.H.; Adank, M.A.; Agata, S.; Andrulis, I.L.; Anton-Culver, H.; et al. Polygenic risk modeling for prediction of epithelial ovarian cancer risk. Eur J Hum Genet 2022, 30, 349-362, doi:10.1038/s41431-021-00987-7.
  7. Biskup, E.; Wils, R.S.; Hogdall, C.; Hogdall, E. Prospects of Improving Early Ovarian Cancer Diagnosis Using Cervical Cell Swabs. Anticancer Res 2022, 42, 1-12, doi:10.21873/anticanres.15451.
  8. Vestergaard, L.K.; Oliveira, D.N.P.; Poulsen, T.S.; Hogdall, C.K.; Hogdall, E.V. Oncomine Comprehensive Assay v3 vs. Oncomine Comprehensive Assay Plus. Cancers (Basel) 2021, 13, doi:10.3390/cancers13205230.
  9. Vestergaard, L.K.; Oliveira, D.N.P.; Høgdall, C.K.; Høgdall, E.V. Next Generation Sequencing Technology in the Clinic and Its Challenges. Cancers (Basel) 2021, 13, doi:10.3390/cancers13081751.
  10. Song, H.; Dicks, E.M.; Tyrer, J.; Intermaggio, M.; Chenevix-Trench, G.; Bowtell, D.D.; Traficante, N.; Group, A.; Brenton, J.; Goranova, T.; et al. Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer. J Med Genet 2021, 58, 305-313, doi:10.1136/jmedgenet-2019-106739.
  11. Quinn, M.C.J.; McCue, K.; Shi, W.; Johnatty, S.E.; Beesley, J.; Civitarese, A.; O’Mara, T.A.; Glubb, D.M.; Tyrer, J.P.; Armasu, S.M.; et al. Identification of a Locus Near ULK1 Associated With Progression-Free Survival in Ovarian Cancer. Cancer Epidemiol Biomarkers Prev 2021, 30, 1669-1680, doi:10.1158/1055-9965.EPI-20-1817.
  12. Vestergaard, L.K.; Høgdall, E.V. Next Generation Sequencing – Hvilke typer undersøgelser er der? Best Practice Nordic. Online article: https://bpno.dk/artikler/next-generation-sequencing.
  13. Prahm, K.P.; Høgdall, C.K.; Karlsen, M.A.; Christensen, I.J.; Novotny, G.W.; Høgdall, E. MicroRNA characteristics in epithelial ovarian cancer. PLoS One 2021, 16, e0252401, doi:10.1371/journal.pone.0252401.
  14. Oliveira, D.; Schnack, T.H.; Poulsen, T.S.; Christiansen, A.P.; Høgdall, C.K.; Høgdall, E.V. Genomic Sub-Classification of Ovarian Clear Cell Carcinoma Revealed by Distinct Mutational Signatures. Cancers (Basel) 2021, 13, doi:10.3390/cancers13205242.
  15. Oliveira, D.; Prahm, K.P.; Christensen, I.J.; Hansen, A.; Høgdall, C.K.; Høgdall, E.V. Gene expression profile association with poor prognosis in epithelial ovarian cancer patients. Sci Rep 2021, 11, 5438, doi:10.1038/s41598-021-84953-9.
  16. Oliveira, D.; Prahm, K.P.; Christensen, I.J.; Hansen, A.; Høgdall, C.K.; Høgdall, E.V. Noncoding RNA (ncRNA) Profile Association with Patient Outcome in Epithelial Ovarian Cancer Cases. Reprod Sci 2021, 28, 757-765, doi:10.1007/s43032-020-00372-7.
  17. Oliveira, D.; Hentze, J.; O’Rourke, C.J.; Andersen, J.B.; Hogdall, C.; Hogdall, E.V. DNA Methylation in Ovarian Tumors-a Comparison Between Fresh Tissue and FFPE Samples. Reprod Sci 2021, 28, 3212-3218, doi:10.1007/s43032-021-00589-0.
  18. Lopacinska-Jørgensen, J.; Oliveira, D.; Wayne Novotny, G.; Høgdall, C.K.; Høgdall, E.V. Integrated microRNA and mRNA signatures associated with overall survival in epithelial ovarian cancer. PLoS One 2021, 16, e0255142, doi:10.1371/journal.pone.0255142.
  19. Kar, S.P.; Considine, D.P.C.; Tyrer, J.P.; Plummer, J.T.; Chen, S.; Dezem, F.S.; Barbeira, A.N.; Rajagopal, P.S.; Rosenow, W.T.; Moreno, F.; et al. Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer. HGG Adv 2021, 2, doi:10.1016/j.xhgg.2021.100042.
  20. Kang, E.Y.; Millstein, J.; Popovic, G.; Meagher, N.S.; Bolithon, A.; Talhouk, A.; Chiu, D.S.; Anglesio, M.S.; Leung, B.; Tang, K.; et al. MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. Virchows Arch 2021, doi:10.1007/s00428-021-03232-0.
  21. Glubb, D.M.; Thompson, D.J.; Aben, K.K.H.; Alsulimani, A.; Amant, F.; Annibali, D.; Attia, J.; Barricarte, A.; Beckmann, M.W.; Berchuck, A.; et al. Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Cancer Epidemiol Biomarkers Prev 2021, 30, 217-228, doi:10.1158/1055-9965.EPI-20-0739.
  22. Faaborg, L.; Fredslund Andersen, R.; Waldstrom, M.; Hogdall, E.; Hogdall, C.; Adimi, P.; Jakobsen, A.; Dahl Steffensen, K. Analysis of HOXA9 methylated ctDNA in ovarian cancer using sense-antisense measurement. Clin Chim Acta 2021, 522, 152-157, doi:10.1016/j.cca.2021.08.020.
  23. Yang, X.; Song, H.; Leslie, G.; Engel, C.; Hahnen, E.; Auber, B.; Horvath, J.; Kast, K.; Niederacher, D.; Turnbull, C.; et al. Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D. J Natl Cancer Inst 2020, 112, 1242-1250, doi:10.1093/jnci/djaa030.
  24. Norell, C.H.; Butler, J.; Farrell, R.; Altman, A.; Bentley, J.; Cabasag, C.J.; Cohen, P.A.; Fegan, S.; Fung-Kee-Fung, M.; Gourley, C.; et al. Exploring international differences in ovarian cancer treatment: a comparison of clinical practice guidelines and patterns of care. Int J Gynecol Cancer 2020, 30, 1748-1756, doi:10.1136/ijgc-2020-001403.
  25. Mosgaard, B.J.; Meaidi, A.; Hogdall, C.; Noer, M.C. Risk factors for early death among ovarian cancer patients: a nationwide cohort study. J Gynecol Oncol 2020, 31, e30, doi:10.3802/jgo.2020.31.e30.
  26. Martins, F.C.; Couturier, D.L.; Paterson, A.; Karnezis, A.N.; Chow, C.; Nazeran, T.M.; Odunsi, A.; Gentry-Maharaj, A.; Vrvilo, A.; Hein, A.; et al. Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. Br J Cancer 2020, 123, 793-802, doi:10.1038/s41416-020-0900-0.
  27. Lee, A.W.; Wu, A.H.; Wiensch, A.; Mukherjee, B.; Terry, K.L.; Harris, H.R.; Carney, M.E.; Jensen, A.; Cramer, D.W.; Berchuck, A.; et al. Estrogen Plus Progestin Hormone Therapy and Ovarian Cancer: A Complicated Relationship Explored. Epidemiology 2020, 31, 402-408, doi:10.1097/EDE.0000000000001175.
  28. Høgdall, E.; Høgdall, C.; Vo, T.; Zhou, W.; Huang, L.; Marton, M.; Keefe, S.M.; Busch-Sørensen, M.; Sørensen, S.M.; Georgsen, J.; et al. Impact of PD-L1 and T-cell inflamed gene expression profile on survival in advanced ovarian cancer. Int J Gynecol Cancer 2020, 30, 1034-1042, doi:10.1136/ijgc-2019-001109.
  29. Hogdall, C.K. [Ovariecancerbehandling i Danmark]. Ugeskr Laeger 2020, 182.
  30. Ekmann-Gade, A.W.; Hogdall, C.K.; Engelholm, S.A.; Fago-Olsen, C.L. Neoadjuvant Chemotherapy Reduces the Treatment-free Interval After First-line Treatment in Patients With Advanced Ovarian Cancer. Anticancer Res 2020, 40, 2765-2770, doi:10.21873/anticanres.14248.
  31. Brieger, K.K.; Peterson, S.; Lee, A.W.; Mukherjee, B.; Bakulski, K.M.; Alimujiang, A.; Anton-Culver, H.; Anglesio, M.S.; Bandera, E.V.; Berchuck, A.; et al. Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. Gynecol Oncol 2020, 158, 702-709, doi:10.1016/j.ygyno.2020.06.481.
  32. Yang, Y.; Wu, L.; Shu, X.; Lu, Y.; Shu, X.O.; Cai, Q.; Beeghly-Fadiel, A.; Li, B.; Ye, F.; Berchuck, A.; et al. Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. Cancer Res 2019, 79, 505-517, doi:10.1158/0008-5472.Can-18-2726.
  33. Sørensen, S.M.; Schnack, T.H.; Høgdall, C. Impact of residual disease on overall survival in women with Federation of Gynecology and Obstetrics stage IIIB-IIIC vs stage IV epithelial ovarian cancer after primary surgery. Acta Obstet Gynecol Scand 2019, 98, 34-43, doi:10.1111/aogs.13453.
  34. Singh, A.; Gupta, S.; Sachan, M. Epigenetic Biomarkers in the Management of Ovarian Cancer: Current Prospectives. Front Cell Dev Biol 2019, 7, 182, doi:10.3389/fcell.2019.00182.
  35. Rask, L.; Høgdall, C.K.; Kjaer, S.K.; Christensen, L.; Jensen, A.; Blaakaer, J.; Christensen, I.J.; Høgdall, E.V.S. Association of CD31 and p53 With Survival of Ovarian Cancer Patients. Anticancer Res 2019, 39, 567-576, doi:10.21873/anticanres.13149.
  36. Oliveira, D.N.P.; Carlsen, A.L.; Heegaard, N.H.H.; Prahm, K.P.; Christensen, I.J.; Hogdall, C.K.; Hogdall, E.V. Diagnostic plasma miRNA-profiles for ovarian cancer in patients with pelvic mass. PLoS One 2019, 14, e0225249, doi:10.1371/journal.pone.0225249.
  37. Minlikeeva, A.N.; Cannioto, R.; Jensen, A.; Kjaer, S.K.; Jordan, S.J.; Diergaarde, B.; Szender, J.B.; Odunsi, K.; Almohanna, H.; Mayor, P.; et al. Joint exposure to smoking, excessive weight, and physical inactivity and survival of ovarian cancer patients, evidence from the Ovarian Cancer Association Consortium. Cancer Causes Control 2019, 30, 537-547, doi:10.1007/s10552-019-01157-3.
  38. Kim, S.; Wang, M.; Tyrer, J.P.; Jensen, A.; Wiensch, A.; Liu, G.; Lee, A.W.; Ness, R.B.; Salvatore, M.; Tworoger, S.S.; et al. A comprehensive gene-environment interaction analysis in Ovarian Cancer using genome-wide significant common variants. Int J Cancer 2019, 144, 2192-2205, doi:10.1002/ijc.32029.
  39. Jiang, X.; Finucane, H.K.; Schumacher, F.R.; Schmit, S.L.; Tyrer, J.P.; Han, Y.; Michailidou, K.; Lesseur, C.; Kuchenbaecker, K.B.; Dennis, J.; et al. Publisher Correction: Shared heritability and functional enrichment across six solid cancers. Nat Commun 2019, 10, 4386, doi:10.1038/s41467-019-12095-8.
  40. Jiang, X.; Finucane, H.K.; Schumacher, F.R.; Schmit, S.L.; Tyrer, J.P.; Han, Y.; Michailidou, K.; Lesseur, C.; Kuchenbaecker, K.B.; Dennis, J.; et al. Shared heritability and functional enrichment across six solid cancers. Nat Commun 2019, 10, 431, doi:10.1038/s41467-018-08054-4.
  41. Ingerslev, K.; Høgdall, E.; Skovrider-Ruminski, W.; Schnack, T.H.; Lidang, M.; Høgdall, C.; Blaakaer, J. The prevalence of EBV and CMV DNA in epithelial ovarian cancer. Infect Agent Cancer 2019, 14, 7, doi:10.1186/s13027-019-0223-z.
  42. Improta, G.; Pettinato, A.; Høgdall, E.; Santeusanio, G.; Vatrano, S.; Fraggetta, F.; Zannoni, G.F. Ovarian Clear Cell Carcinoma: From Morphology to Molecular Biology. Appl Immunohistochem Mol Morphol 2019, 27, 631-636, doi:10.1097/pai.0000000000000662.
  43. Hentze, J.L.; Kringelbach, T.M.; Novotny, G.W.; Hamid, B.H.; Ravn, V.; Christensen, I.J.; Høgdall, C.; Høgdall, E. Optimized Biobanking Procedures for Preservation of RNA in Tissue: Comparison of Snap-Freezing and RNAlater-Fixation Methods. Biopreserv Biobank 2019, 17, 562-569, doi:10.1089/bio.2019.0028.
  44. Hentze, J.L.; Høgdall, C.K.; Høgdall, E.V. Methylation and ovarian cancer: Can DNA methylation be of diagnostic use? Mol Clin Oncol 2019, 10, 323-330, doi:10.3892/mco.2019.1800.
  45. Hengeveld, E.M.; Zusterzeel, P.L.M.; Lajer, H.; Høgdall, C.K.; Rosendahl, M. The value of surgical staging in patients with apparent early stage epithelial ovarian carcinoma. Gynecol Oncol 2019, 154, 308-313, doi:10.1016/j.ygyno.2019.06.006.
  46. Harris, H.R.; Cushing-Haugen, K.L.; Webb, P.M.; Nagle, C.M.; Jordan, S.J.; Australian Ovarian Cancer Study, G.; Risch, H.A.; Rossing, M.A.; Doherty, J.A.; Goodman, M.T.; et al. Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study. Int J Epidemiol 2019, 48, 822-830, doi:10.1093/ije/dyz113.
  47. Christophersen, M.K.; Høgdall, C.; Høgdall, E. The prospect of discovering new biomarkers for ovarian cancer based on current knowledge of susceptibility loci and genetic variation (Review). Int J Mol Med 2019, 44, 1599-1608, doi:10.3892/ijmm.2019.4352.
  48. Christensen, M.V.; Høgdall, C.; Jensen, S.G.; Lokman, N.; Ricciardelli, C.; Christensen, I.J.; Christiansen, P.; Brask, J.; Karlsen, M.A.; Nissen, T.K.; et al. Annexin A2 and S100A10 as Candidate Prognostic Markers in Epithelial Ovarian Cancer. Anticancer Res 2019, 39, 2475-2482, doi:10.21873/anticanres.13367.
  49. Van Nieuwenhuysen, E.; Busschaert, P.; Neven, P.; Han, S.N.; Moerman, P.; Liontos, M.; Papaspirou, M.; Kupryjanczyk, J.; Hogdall, C.; Hogdall, E.; et al. The genetic landscape of 87 ovarian germ cell tumors. Gynecol Oncol 2018, 151, 61-68, doi:10.1016/j.ygyno.2018.08.013.
  50. Seibæk, L.; Jakobsen, D.H.; Høgdall, C. The Danish Gynecological Cancer Nursing Database: Creating Evidence for Quality Improvements in Preoperative and Postoperative Cancer Care. Int J Gynecol Cancer 2018, 28, 802-807, doi:10.1097/igc.0000000000001220.
  51. Rosendahl, M.; Harter, P.; Bjørn, S.F.; Høgdall, C. Specific Regions, Rather than the Entire Peritoneal Carcinosis Index, are Predictive of Complete Resection and Survival in Advanced Epithelial Ovarian Cancer. Int J Gynecol Cancer 2018, 28, 316-322, doi:10.1097/igc.0000000000001173.
  52. Prahm, K.P.; Hogdall, C.; Karlsen, M.A.; Christensen, I.J.; Novotny, G.W.; Hogdall, E. Identification and validation of potential prognostic and predictive miRNAs of epithelial ovarian cancer. PLoS One 2018, 13, e0207319, doi:10.1371/journal.pone.0207319.
  53. Noer, M.C.; Leandersson, P.; Paulsen, T.; Rosthoj, S.; Antonsen, S.L.; Borgfeldt, C.; Hogdall, C. Confounders other than comorbidity explain survival differences in Danish and Swedish ovarian cancer patients – a comparative cohort study. Acta Oncol 2018, 57, 1100-1108, doi:10.1080/0284186X.2018.1440085.
  54. Noer, M.C.; Antonsen, S.L.; Ottesen, B.; Christensen, I.J.; Hogdall, C. Type I Versus Type II Endometrial Cancer: Differential Impact of Comorbidity. Int J Gynecol Cancer 2018, 28, 586-593, doi:10.1097/IGC.0000000000001184.
  55. Mueller, J.J.; Lajer, H.; Mosgaard, B.J.; Bach Hamba, S.; Morice, P.; Gouy, S.; Hussein, Y.; Soslow, R.A.; Schlappe, B.A.; Zhou, Q.C.; et al. International Study of Primary Mucinous Ovarian Carcinomas Managed at Tertiary Medical Centers. Int J Gynecol Cancer 2018, 28, 915-924, doi:10.1097/igc.0000000000001263.
  56. Lu, Y.; Beeghly-Fadiel, A.; Wu, L.; Guo, X.; Li, B.; Schildkraut, J.M.; Im, H.K.; Chen, Y.A.; Permuth, J.B.; Reid, B.M.; et al. A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 2018, 78, 5419-5430, doi:10.1158/0008-5472.Can-18-0951.
  57. Kelemen, L.E.; Earp, M.; Fridley, B.L.; Chenevix-Trench, G.; Australian Ovarian Cancer Study, G.; Fasching, P.A.; Beckmann, M.W.; Ekici, A.B.; Hein, A.; Lambrechts, D.; et al. rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. Int J Mol Sci 2018, 19, doi:10.3390/ijms19092473.
  58. Idorn, M.; Olsen, M.; Halldorsdottir, H.R.; Skadborg, S.K.; Pedersen, M.; Hogdall, C.; Hogdall, E.; Met, O.; Thor Straten, P. Improved migration of tumor ascites lymphocytes to ovarian cancer microenvironment by CXCR2 transduction. Oncoimmunology 2018, 7, e1412029, doi:10.1080/2162402X.2017.1412029.
  59. Hedbäck, N.E.; Karlsen, M.A.; Høgdall, C.K.; Rosendahl, M. Survival of selected patients with ovarian cancer treated with fertility-sparing surgery. Reprod Biomed Online 2018, 37, 71-76, doi:10.1016/j.rbmo.2018.03.018.
  60. Earp, M.; Tyrer, J.P.; Winham, S.J.; Lin, H.Y.; Chornokur, G.; Dennis, J.; Aben, K.K.H.; Anton-Culver, H.; Antonenkova, N.; Bandera, E.V.; et al. Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. PLoS One 2018, 13, e0197561, doi:10.1371/journal.pone.0197561.
  61. Dixon-Suen, S.C.; Nagle, C.M.; Thrift, A.P.; Pharoah, P.D.P.; Ewing, A.; Pearce, C.L.; Zheng, W.; Australian Ovarian Cancer Study, G.; Chenevix-Trench, G.; Fasching, P.A.; et al. Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. Br J Cancer 2018, 118, 1123-1129, doi:10.1038/s41416-018-0011-3.
  62. Christensen, M.V.; Høgdall, C.K.; Jochumsen, K.M.; Høgdall, E.V.S. Annexin A2 and cancer: A systematic review. Int J Oncol 2018, 52, 5-18, doi:10.3892/ijo.2017.4197.
  63. Sucheston-Campbell, L.E.; Cannioto, R.; Clay, A.I.; Etter, J.L.; Eng, K.H.; Liu, S.; Battaglia, S.; Hu, Q.; Szender, J.B.; Minlikeeva, A.; et al. No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. Cancer Epidemiol Biomarkers Prev 2017, 26, 420-424, doi:10.1158/1055-9965.Epi-16-0631.
  64. Schnack, T.H.; Hogdall, E.; Thomsen, L.N.; Hogdall, C. Demographic, Clinical, and Prognostic Factors of Ovarian Clear Cell Adenocarcinomas According to Endometriosis Status. Int J Gynecol Cancer 2017, 27, 1804-1812, doi:10.1097/IGC.0000000000001102.
  65. Rosendahl, M.; Haueberg Oester, L.A.; Høgdall, C.K. The Importance of Appendectomy in Surgery for Mucinous Adenocarcinoma of the Ovary. Int J Gynecol Cancer 2017, 27, 430-436, doi:10.1097/igc.0000000000000910.
  66. Prahm, K.P.; Hogdall, C.; Karlsen, M.A.; Christensen, I.J.; Novotny, G.W.; Knudsen, S.; Hansen, A.; Jensen, P.B.; Jensen, T.; Mirza, M.R.; et al. Clinical validation of chemotherapy predictors developed on global microRNA expression in the NCI60 cell line panel tested in ovarian cancer. PLoS One 2017, 12, e0174300, doi:10.1371/journal.pone.0174300.
  67. Praestegaard, C.; Jensen, A.; Jensen, S.M.; Nielsen, T.S.; Webb, P.M.; Nagle, C.M.; DeFazio, A.; Australian Ovarian Cancer Study, G.; Hogdall, E.; Rossing, M.A.; et al. Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies. Int J Cancer 2017, 140, 2422-2435, doi:10.1002/ijc.30600.
  68. Phelan, C.M.; Kuchenbaecker, K.B.; Tyrer, J.P.; Kar, S.P.; Lawrenson, K.; Winham, S.J.; Dennis, J.; Pirie, A.; Riggan, M.J.; Chornokur, G.; et al. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet 2017, 49, 680-691, doi:10.1038/ng.3826.
  69. Noer, M.C.; Sperling, C.D.; Ottesen, B.; Antonsen, S.L.; Christensen, I.J.; Høgdall, C. Ovarian Cancer and Comorbidity: Is Poor Survival Explained by Choice of Primary Treatment or System Delay? Int J Gynecol Cancer 2017, 27, 1123-1133, doi:10.1097/igc.0000000000001001.
  70. Kar, S.P.; Adler, E.; Tyrer, J.; Hazelett, D.; Anton-Culver, H.; Bandera, E.V.; Beckmann, M.W.; Berchuck, A.; Bogdanova, N.; Brinton, L.; et al. Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. Br J Cancer 2017, 116, 524-535, doi:10.1038/bjc.2016.426.
  71. Ingerslev, K.; Hogdall, E.; Schnack, T.H.; Skovrider-Ruminski, W.; Hogdall, C.; Blaakaer, J. The potential role of infectious agents and pelvic inflammatory disease in ovarian carcinogenesis. Infect Agent Cancer 2017, 12, 25, doi:10.1186/s13027-017-0134-9.
  72. Hentze, J.L.; Høgdall, C.; Kjær, S.K.; Blaakær, J.; Høgdall, E. Searching for new biomarkers in ovarian cancer patients: Rationale and design of a retrospective study under the Mermaid III project. Contemp Clin Trials Commun 2017, 8, 167-174, doi:10.1016/j.conctc.2017.10.003.
  73. Glubb, D.M.; Johnatty, S.E.; Quinn, M.C.J.; O’Mara, T.A.; Tyrer, J.P.; Gao, B.; Fasching, P.A.; Beckmann, M.W.; Lambrechts, D.; Vergote, I.; et al. Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci. Oncotarget 2017, 8, 64670-64684, doi:10.18632/oncotarget.18501.
  74. Bjørn, S.F.; Schnack, T.H.; Lajer, H.; Christensen, I.J.; Lundvall, L.; Thomsen, L.N.; Høgdall, C. Classification of Ovarian Cancer Surgery Facilitates Treatment Decisions in a Gynecological Multidisciplinary Team. Int J Gynecol Cancer 2017, 27, 382-389, doi:10.1097/igc.0000000000000876.
  75. Babic, A.; Cramer, D.W.; Kelemen, L.E.; Köbel, M.; Steed, H.; Webb, P.M.; Johnatty, S.E.; deFazio, A.; Lambrechts, D.; Goodman, M.T.; et al. Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium. Cancer Causes Control 2017, 28, 459-468, doi:10.1007/s10552-016-0841-3.
  76. Aarenstrup Karlsen, M.; Hogdall, C.; Nedergaard, L.; Philipsen Prahm, K.; Schou Karlsen, N.M.; Weng Ekmann-Gade, A.; Henrichsen Schnack, T.; Svenstrup Poulsen, T.; Jarle Christensen, I.; Hogdall, E. HE4 as a predictor of adjuvant chemotherapy resistance and survival in patients with epithelial ovarian cancer. APMIS 2016, 124, 1038-1045, doi:10.1111/apm.12625.
  77. Southey, M.C.; Goldgar, D.E.; Winqvist, R.; Pylkas, K.; Couch, F.; Tischkowitz, M.; Foulkes, W.D.; Dennis, J.; Michailidou, K.; van Rensburg, E.J.; et al. PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. J Med Genet 2016, 53, 800-811, doi:10.1136/jmedgenet-2016-103839.
  78. Sorensen, S.M.; Bjorn, S.F.; Jochumsen, K.M.; Jensen, P.T.; Thranov, I.R.; Hare-Bruun, H.; Seibaek, L.; Hogdall, C. Danish Gynecological Cancer Database. Clin Epidemiol 2016, 8, 485-490, doi:10.2147/CLEP.S99479.
  79. Schnack, T.H.; Hogdall, E.; Nedergaard, L.; Hogdall, C. Demographic Clinical and Prognostic Factors of Primary Ovarian Adenocarcinomas of Serous and Clear Cell Histology-A Comparative Study. Int J Gynecol Cancer 2016, 26, 82-90, doi:10.1097/IGC.0000000000000585.
  80. Rosendahl, M.; Mosgaard, B.J.; Høgdall, C. The Influence of Cyst Emptying, Lymph Node Resection and Chemotherapy on Survival in Stage IA and IC1 Epithelial Ovarian Cancer. Anticancer Res 2016, 36, 5373-5379, doi:10.21873/anticanres.11111.
  81. Rosendahl, M.; Høgdall, C.K.; Mosgaard, B.J. Restaging and Survival Analysis of 4036 Ovarian Cancer Patients According to the 2013 FIGO Classification for Ovarian, Fallopian Tube, and Primary Peritoneal Cancer. Int J Gynecol Cancer 2016, 26, 680-687, doi:10.1097/igc.0000000000000675.
  82. Prahm, K.P.; Novotny, G.W.; Hogdall, C.; Hogdall, E. Current status on microRNAs as biomarkers for ovarian cancer. APMIS 2016, 124, 337-355, doi:10.1111/apm.12514.
  83. Permuth, J.B.; Reid, B.; Earp, M.; Chen, Y.A.; Monteiro, A.N.; Chen, Z.; Group, A.S.; Chenevix-Trench, G.; Fasching, P.A.; Beckmann, M.W.; et al. Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. Oncotarget 2016, 7, 72381-72394, doi:10.18632/oncotarget.10546.
  84. Ovarian Cancer Association Consortium, B.C.A.C.; Consortium of Modifiers of, B.; Brca; Hollestelle, A.; van der Baan, F.H.; Berchuck, A.; Johnatty, S.E.; Aben, K.K.; Agnarsson, B.A.; Aittomaki, K.; et al. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol 2016, 141, 386-401, doi:10.1016/j.ygyno.2015.04.034.
  85. Ong, J.S.; Cuellar-Partida, G.; Lu, Y.; Australian Ovarian Cancer, S.; Fasching, P.A.; Hein, A.; Burghaus, S.; Beckmann, M.W.; Lambrechts, D.; Van Nieuwenhuysen, E.; et al. Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. Int J Epidemiol 2016, 45, 1619-1630, doi:10.1093/ije/dyw207.
  86. Noer, M.C.; Sperling, C.D.; Antonsen, S.L.; Ottesen, B.; Christensen, I.J.; Høgdall, C. A new clinically applicable age-specific comorbidity index for preoperative risk assessment of ovarian cancer patients. Gynecol Oncol 2016, 141, 471-478, doi:10.1016/j.ygyno.2016.03.034.
  87. Meeks, H.D.; Song, H.; Michailidou, K.; Bolla, M.K.; Dennis, J.; Wang, Q.; Barrowdale, D.; Frost, D.; Embrace; McGuffog, L.; et al. BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. J Natl Cancer Inst 2016, 108, doi:10.1093/jnci/djv315.
  88. Lawrenson, K.; Kar, S.; McCue, K.; Kuchenbaeker, K.; Michailidou, K.; Tyrer, J.; Beesley, J.; Ramus, S.J.; Li, Q.; Delgado, M.K.; et al. Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nat Commun 2016, 7, 12675, doi:10.1038/ncomms12675.
  89. Karlsen, N.M.S.; Karlsen, M.A.; Høgdall, E.; Nedergaard, L.; Christensen, I.J.; Høgdall, C. Relapse and disease specific survival in 1143 Danish women diagnosed with borderline ovarian tumours (BOT). Gynecol Oncol 2016, 142, 50-53, doi:10.1016/j.ygyno.2016.05.005.
  90. Karlsen, M.A.; Fagö-Olsen, C.; Høgdall, E.; Schnack, T.H.; Christensen, I.J.; Nedergaard, L.; Lundvall, L.; Lydolph, M.C.; Engelholm, S.A.; Høgdall, C. A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIIC-IV ovarian cancer-a part of the Danish prospective pelvic mass study. Tumour Biol 2016, 37, 12619-12626, doi:10.1007/s13277-016-5166-z.
  91. Ingerslev, K.; Hogdall, E.; Skovrider-Ruminski, W.; Schnack, T.H.; Karlsen, M.A.; Nedergaard, L.; Hogdall, C.; Blaakær, J. High-risk HPV is not associated with epithelial ovarian cancer in a Caucasian population. Infect Agent Cancer 2016, 11, 39, doi:10.1186/s13027-016-0087-4.
  92. Høgdall, E. Approaches to the detection of ovarian cancer. Scand J Clin Lab Invest Suppl 2016, 245, S49-53, doi:10.1080/00365513.2016.1208452.
  93. Hampras, S.S.; Sucheston-Campbell, L.E.; Cannioto, R.; Chang-Claude, J.; Modugno, F.; Dörk, T.; Hillemanns, P.; Preus, L.; Knutson, K.L.; Wallace, P.K.; et al. Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget 2016, 7, 69097-69110, doi:10.18632/oncotarget.10215.
  94. French, J.D.; Johnatty, S.E.; Lu, Y.; Beesley, J.; Gao, B.; Kalimutho, M.; Henderson, M.J.; Russell, A.J.; Kar, S.; Chen, X.; et al. Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer. Oncotarget 2016, 7, 6353-6368, doi:10.18632/oncotarget.7047.
  95. Edwards, H.M.; Noer, M.C.; Sperling, C.D.; Nguyen-Nielsen, M.; Lundvall, L.; Christensen, I.J.; Høgdall, C. Survival of ovarian cancer patients in Denmark: Results from the Danish gynaecological cancer group (DGCG) database, 1995-2012. Acta Oncol 2016, 55 Suppl 2, 36-43, doi:10.1080/0284186x.2016.1182641.
  96. Dixon, S.C.; Nagle, C.M.; Thrift, A.P.; Pharoah, P.D.; Pearce, C.L.; Zheng, W.; Painter, J.N.; Chenevix-Trench, G.; Fasching, P.A.; Beckmann, M.W.; et al. Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. Int J Epidemiol 2016, 45, 884-895, doi:10.1093/ije/dyw158.
  97. Cuellar-Partida, G.; Lu, Y.; Dixon, S.C.; Australian Ovarian Cancer, S.; Fasching, P.A.; Hein, A.; Burghaus, S.; Beckmann, M.W.; Lambrechts, D.; Van Nieuwenhuysen, E.; et al. Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Hum Genet 2016, 135, 741-756, doi:10.1007/s00439-016-1663-9.
  98. Bolton, K.L.; Tyrer, J.; Song, H.; Ramus, S.J.; Notaridou, M.; Jones, C.; Sher, T.; Gentry-Maharaj, A.; Wozniak, E.; Tsai, Y.Y.; et al. Corrigendum: Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet 2016, 48, 101, doi:10.1038/ng0116-101b.
  99. Thomsen, J.; Hjortebjerg, R.; Espelund, U.; Ørtoft, G.; Vestergaard, P.; Magnusson, N.E.; Conover, C.A.; Tramm, T.; Hager, H.; Høgdall, C.; et al. PAPP-A proteolytic activity enhances IGF bioactivity in ascites from women with ovarian carcinoma. Oncotarget 2015, 6, 32266-32278, doi:10.18632/oncotarget.5010.
  100. Sørensen, R.D.; Schnack, T.H.; Karlsen, M.A.; Høgdall, C.K. Serous ovarian, fallopian tube and primary peritoneal cancers: a common disease or separate entities – a systematic review. Gynecol Oncol 2015, 136, 571-581, doi:10.1016/j.ygyno.2015.01.534.
  101. Song, H.; Dicks, E.; Ramus, S.J.; Tyrer, J.P.; Intermaggio, M.P.; Hayward, J.; Edlund, C.K.; Conti, D.; Harrington, P.; Fraser, L.; et al. Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population. J Clin Oncol 2015, 33, 2901-2907, doi:10.1200/jco.2015.61.2408.
  102. Prahm, K.P.; Karlsen, M.A.; Høgdall, E.; Scheller, N.M.; Lundvall, L.; Nedergaard, L.; Christensen, I.J.; Høgdall, C. The prognostic value of dividing epithelial ovarian cancer into type I and type II tumors based on pathologic characteristics. Gynecol Oncol 2015, 136, 205-211, doi:10.1016/j.ygyno.2014.12.029.
  103. Nagle, C.M.; Dixon, S.C.; Jensen, A.; Kjaer, S.K.; Modugno, F.; deFazio, A.; Fereday, S.; Hung, J.; Johnatty, S.E.; Australian Ovarian Cancer Study, G.; et al. Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium. Br J Cancer 2015, 113, 817-826, doi:10.1038/bjc.2015.245.
  104. Lee, A.W.; Tyrer, J.P.; Doherty, J.A.; Stram, D.A.; Kupryjanczyk, J.; Dansonka-Mieszkowska, A.; Plisiecka-Halasa, J.; Spiewankiewicz, B.; Myers, E.J.; Australian Cancer, S.; et al. Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study. Gynecol Oncol 2015, 136, 542-548, doi:10.1016/j.ygyno.2014.12.017.
  105. Lawrenson, K.; Li, Q.; Kar, S.; Seo, J.H.; Tyrer, J.; Spindler, T.J.; Lee, J.; Chen, Y.; Karst, A.; Drapkin, R.; et al. Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nat Commun 2015, 6, 8234, doi:10.1038/ncomms9234.
  106. Lawrenson, K.; Iversen, E.S.; Tyrer, J.; Weber, R.P.; Concannon, P.; Hazelett, D.J.; Li, Q.; Marks, J.R.; Berchuck, A.; Lee, J.M.; et al. Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. Carcinogenesis 2015, 36, 1341-1353, doi:10.1093/carcin/bgv138.
  107. Kuchenbaecker, K.B.; Ramus, S.J.; Tyrer, J.; Lee, A.; Shen, H.C.; Beesley, J.; Lawrenson, K.; McGuffog, L.; Healey, S.; Lee, J.M.; et al. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet 2015, 47, 164-171, doi:10.1038/ng.3185.
  108. Karlsen, M.A.; Høgdall, E.V.; Christensen, I.J.; Borgfeldt, C.; Kalapotharakos, G.; Zdrazilova-Dubska, L.; Chovanec, J.; Lok, C.A.; Stiekema, A.; Mutz-Dehbalaie, I.; et al. A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer – An international multicenter study in women with an ovarian mass. Gynecol Oncol 2015, 138, 640-646, doi:10.1016/j.ygyno.2015.06.021.
  109. Johnatty, S.E.; Tyrer, J.P.; Kar, S.; Beesley, J.; Lu, Y.; Gao, B.; Fasching, P.A.; Hein, A.; Ekici, A.B.; Beckmann, M.W.; et al. Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. Clin Cancer Res 2015, 21, 5264-5276, doi:10.1158/1078-0432.Ccr-15-0632.
  110. Jim, H.S.; Lin, H.Y.; Tyrer, J.P.; Lawrenson, K.; Dennis, J.; Chornokur, G.; Chen, Z.; Chen, A.Y.; Permuth-Wey, J.; Aben, K.K.; et al. Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). J Genet Genome Res 2015, 2, doi:10.23937/2378-3648/1410017.
  111. Heeran, M.C.; Rask, L.; Hogdall, C.K.; Kjaer, S.K.; Christensen, L.; Jensen, A.; Blaakaer, J.; Jarle Christensen, I.B.; Hogdall, E.V. Tetranectin positive expression in tumour tissue leads to longer survival in Danish women with ovarian cancer. APMIS 2015, 123, 401-409, doi:10.1111/apm.12368.
  112. Gosvig, C.F.; Kjaer, S.K.; Blaakær, J.; Høgdall, E.; Høgdall, C.; Jensen, A. Coffee, tea, and caffeine consumption and risk of epithelial ovarian cancer and borderline ovarian tumors: Results from a Danish case-control study. Acta Oncol 2015, 54, 1144-1151, doi:10.3109/0284186x.2014.1001035.
  113. Chornokur, G.; Lin, H.Y.; Tyrer, J.P.; Lawrenson, K.; Dennis, J.; Amankwah, E.K.; Qu, X.; Tsai, Y.Y.; Jim, H.S.; Chen, Z.; et al. Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. PLoS One 2015, 10, e0128106, doi:10.1371/journal.pone.0128106.
  114. Amankwah, E.K.; Lin, H.Y.; Tyrer, J.P.; Lawrenson, K.; Dennis, J.; Chornokur, G.; Aben, K.K.; Anton-Culver, H.; Antonenkova, N.; Bruinsma, F.; et al. Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genet Epidemiol 2015, 39, 689-697, doi:10.1002/gepi.21921.

PUBLICATIONS MERMAID III – The Infection Theory

Ingerslev K, Hogdall E, Schnack TH, Skovrider-Ruminski W, Hogdall C, Blaakaer J

The potential role of infectious agents and pelvic inflammatory disease in ovarian

Carcinogenesis.

Infectious Agents and Cancer (2017) 12:25 DOI 10.1186/s13027-017-0134-9

 

Ingerslev K, Hogdall E, Skovrider-Ruminski W,  Schnack TH, Aarenstrup Karlsen M, Nedergaard L, Hogdall C, Blaakær J.

High-risk HPV is not associated with epithelial ovarian cancer in a Caucasian population

Infectious Agents and Cancer (2016) 11:39 DOI 10.1186/s13027-016-0087-4

 

Thomsen LH, Schnack TH, Buchardi K, Hummelshøj L, Missmer SA, Forman A, Blaakær J.

Risk factors of epithelial ovarian carcinomas among women with endometriosis: a systematic review.

Acta Obstet Gynecol Scand 2016. doi: 10.1111/aogs.13010.

 

Kasper SM, Dueholm M, Marinovskij E, Blaakær J.

Imaging diagnostics in ovarian cancer: magnetic resonance imaging and a scoring system guiding choice of primary treatment.

European Journal of Obstetrics & Gynecology and Reproductive Biology 210 (2017) 83–89.

 

Posters

Carcinose congress in Wasington:

Mikkelsen MS, Petersen LK, Blaakaer J, Iversen LH

Prevention of prolonged paralytic ileus after treatment of advanced ovarian cancer with cytoreductive surgery and HIPEC

 

Ph.D. day at Aarhus University:
Mikkelsen MS, Iversen LH, Blaakaer J, Petersen LK.

Hypertherm intraperitoneal chemotherapy (HIPEC) used in treatment of advanced ovarian cancer

Publications of MERMAID II and MERMAID I in the following

MERMAID II - -
Nielsen A, Kjaer SK, Munk C, Iftner T Type-specific HPV infection and multiple HPV types: prevalence and risk factor profile in nearly 12,000 younger and older Danish women. Sexual Transmitted Diseases 2008; 35:276-282
Kjaer SK, Breugelmans G, Munk C, Junge J, Watson M, Iftner T. Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark. International Journal of Cancer 2008 15; 123(8):1864-70
Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, de Sanjose S, Naucler P, Lloveras B, Kjaer S, Cuzick J, van Ballegooijen M, Clavel C, Iftner T; Joint European Cohort Study. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008 Oct 13;337:a1754.
Nielsen A, Iftner T, Munk C, Kjaer SK. Acquisition of high-risk human papillomavirus infection in a population-based cohort of Danish women. Sexual Transmitted Diseases 2009; 36(10):609-15
Nielsen A, Kjaer SK, Munk C, Osler M, Iftner T. Persistence of high-risk human papillomavirus infection in a population-based cohort of Danish women. Journal of Medical Virology 2010 ; 82(4):616-23
Kjaer SK. Frederiksen K, Munk C, Iftner T. Long-term absolute risk of CIN3 or worse following one positive test or persistence of different individual HPV types J Natl Cancer Inst. 2010 Oct 6;102(19):1478-88
Jensen KE, Munk C, Sparen P, Tryggvadottir L, Liaw KL, Dasbach E, Nygård M, Kjaer SK. Women's sexual behavior. Population-based study among 65 000 women from four Nordic countries before introduction of human papillomavirus vaccination. Acta Obstet Gynecol Scand. 2011 May;90(5):459-467. doi: 10.1111/j.1600-0412.2010.01066.x. Epub 2011 Feb 5.
Olesen, TB, Jensen KE, Nygård M, Tryggvadottir L, Sparén P, Hansen BT, Liaw K-L, Kjær SK. Young age at first sexual intercourse and subsequent risk-taking behaviours – A population-based study of nearly 65,000 women in four Nordic countries Eur J Public Health 2012 Apr;22(2):220-4. doi: Epub 2011 May 19.
Buttmann N, Nielsen A, Munk C, Liaw KL, Kjaer SK. Sexual risk taking behaviour: prevalence and associated factors. A population-based study of 22 000 Danish men. BMC Public Health. 2011 Oct 5;11(1):764. [Epub ahead of print]
Gheit T, Cornet I, Clifford CM, Iftner T, Munk C, Tommasino M, Kjaer SK Risks for Persistence and Progression by Human Papillomavirus Type 16 variant lineages among a population-based sample of Danish Women. Cancer Epidemiol Biomarkers and Prev 2011; Jul;20(7):1315-21. Epub 2011 Apr 28.
Tuxen M, Nielsen A, Nygaard M, Sparén P, Tryggvadottir L, Hansen BT, Liaw K-L, Kjær SK. Chlamydia, Herpes, Trichomonas and Gonorrhea - Prevalence and risk factors among nearly 70,000 randomly selected women in four Nordic countries. Sex Transm Dis. 2011 Aug;38(8):727-734.
Baandrup L , Munk C , Andersen KK, Junge J, Iftner T, Kjaer SK. HPV16 is Associated with Younger Age in Women with Cervical Intraepithelial Neoplasia Grade 2 and 3. Gynecol Oncol. 2012 Feb;124(2):281-5. Epub 2011 Oct 25.
Rinaldi S, Plummer M, Biessy C, Castellsague X, Overvad K, Krüger Kjær S, Tjonneland AA, Clavel-Chapelon F, Chabbert-Buffet N, Mesrine S, Lukanova A, Kaaks R, Weikert C, Boeing H, Trichopoulou A, Lagiou P, Trichopoulos D, Palli D, Agnoli C, Tumino R, Vineis P, Panico S, Bueno-de-Mesquita HB, van Kranen HJ, Peeters PH, Bakken K, Lund E, Torhild Gram I, Rodriguez L, Bosch FX, Sanchez MJ, Dorronsoro M, Navarro C, Barricarte Gurrea A, Kjellberg LD, Dillner J, Manjer J, Butt S, Khaw KT, Wareham NJ, Allen NE, Travis RC, Romieu II, Ferrari P, Riboli E, Franceschi S. Endogenous sex steroids and risk of cervical carcinoma: results from the EPIC study. Cancer Epidemiology Biomarkers Prev. 2011 Oct 12. [Epub ahead of print]
Plummer M, Peto J, Franceshi S on behalf of the International Collaboration of Epidemiological Studies of Cervical Cancer. Time since first sexual intercourse and the risk of cervical cancer. Int J Cancer 2011 Jun 23. doi: 10. 1002/ijc.26250. [Epub ahead of print]
Iftner T, Eberle S, Iftner A, Holz B, Banik N, Quint W, Straube AN. Prevalence of low-risk and high-risk types of human papillomavirus and other risk factors for HPV infection in Germany within different age groups in women up to 30 years of age: an epidemiological observational study J Med Virol. 2010 Nov;82(11):1928-39.
Stoler MH, Vichnin MD, Ferenczy A, Ferris DG, Perez G, Paavonen J, Joura EA, Djursing H, Sigurdsson K, Jefferson L, Alvarez F, Sings HL, Lu S, James MK, Saah A, Haupt RM; FUTURE I, II and III Investigators The accuracy of colposcopic biopsy: analyses from the placebo arm of the Gardasil clinical trials. Int J Cancer. 2011 Mar 15;128(6):1354-62. doi: 10.1002/ijc.25470.
Ault KA, Joura EA, Kjaer SK, Iversen OE, Wheeler CM, Perez G, Brown DR, Koutsky LA, Garland SM, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Majewski S, Muñoz N, Sings HL, Harkins K, Rutkowski MA, Haupt RM, Garner EI; FUTURE I and II Study Group. Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccine. Int J Cancer. 2011 Mar 15;128(6):1344-53. doi: 10.1002/ijc.25723. Epub 2011 Jan 12.
Lehtinen M, Ault KA, Lyytikainen E, Dillner J, Garland SM, Ferris DG, Koutsky LA, Sings HL, Lu S, Haupt RM, Paavonen J; FUTURE I and II Study Group. Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia. Sex Transm Infect. 2011 Aug;87(5):372-6. Epub 2011 Apr 6.
Haupt RM, Wheeler CM, Brown DR, Garland SM, Ferris DG, Paavonen JA, Lehtinen MO, Steben M, Joura EA, Giacoletti KE, Radley DR, James MK, Saah AJ, Sings HL; FUTURE I and II Investigators. Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection. Int J Cancer. 2011 Dec 1;129(11):2632-42. doi: 10.1002/ijc.25940. Epub 2011 Apr 13.
Reiser J, Hurst J, Voges M, Krauss P, Münch P, Iftner T, Stubenrauch F High-risk human papillomaviruses repress constitutive kappa interferon transcription via E6 to prevent pathogen recognition receptor and antiviral-gene expression. J Virol. 2011 Nov;85(21):11372-80.
Blomberg M, Friis S, Munk C, Bautz A, Kjaer SK. Genital warts and risk of cancer – a Danish study of nearly 50,000 patients with genital warts Journal of Infectious Diseases 2012 May 15;205(10):1544-53. Epub 2012 Mar 15.
Manawapat A, Stubenrauch F, Russ R, Munk C, Kjær SK, Iftner T. Physical state and viral load as predictive biomarkers for persistence and progression of HPV16-positive cervical lesions: results from a population based long-term prospective cohort study. J Sexually Transmitted. Infections 2012 Dec;88(8):627-32. doi: 10.1136/sextrans-2011-050307. Epub 2012 Jul 6.
Nielsen A, Iftner T, Nørgaard M, Munk C, Cohet C, Junge J, Kjaer SK Importance of type-specific low-risk human papillomavirus infection for the risk of abnormal cervical cytology/histology in more than 40,000 Danish women. Cancer Epidemiol Biomarkers Prev. 2012 May;21(5):835-42. Epub 2012 Mar 20.
Ibfelt E, Kjær SK, Johansen C, Høgdall C, Steding-Jessen M, Frederiksen K, Birgitte Frederiksen3, Merete Osler3, Susanne Oksbjerg Dalton Socioeconomic position in relation to stage at diagnosis of cervical cancer and the mediation of comorbidity and smear testing in Danish patients diagnosed 2005-09 Cancer Epidemiol Biomarkers Prev. 2012 Nov;21(11):1949-55.
Jensen KE, Schmiedel S, Frederiksen K, Norrild B, Iftner T, Kruger Kjær S. Risk for cervical intraepithelial neoplasia grade 3 or worse in relation to smoking among women with persistent human papillomavirus infection. Cancer Epidemiol Biomarkers Prev. 2012 Nov;21(11):1949-55.
Jensen KE, Schmiedel S, Norrild B, Frederiksen K, Iftner T, Kjaer SK. Risk of HSIL in HPV positive. Parity as a cofactor for high-grade cervical disease among women with persistent human papillomavirus infection: a 13-year follow-up. Br J Cancer. 2012 Nov 20. doi: 10.1038/bjc.2012.513.
Baandrup L, Blomberg M, Dehlendorff, Sand C, Andersen KK, Kjaer SK. Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. Sexually Trans Dis 2012
Dartell M, Rasch V, Kahesa C, Mwaiselage J, Ngoma T, Junge J, Gernow A, Ejlersen SF, Munk C, Iftner T, Kjaer SK. HPV prevalence and type distribution in 3603 HIV positive and HIV negative women in the general population of Tanzania: the PROTECT study. Sexually Transmitted Diseases 2012 Mar;39(3):201-208.
Joura EA, Garland SM, Paavonen J, Ferris DG, Perez G, Ault KA, Huh WK, Sings HL, James MK, Haupt RM; for the FUTURE I and II Study Group Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ. 2012 Mar 27;344:e1401. doi: 10.1136/bmj.e1401
Castellsagué X, Iftner T, Roura E, Vidart JA, Kjaer SK, Bosch FX, Muñoz N, Palacios S, Rodriguez MS, Serradell L, Torcel-Pagnon L, Cortes J; for the CLEOPATRE Spain Study Group. Prevalence and genotype distribution of human papillomavirus infection of the cervix in Spain: The CLEOPATRE study. J Med Virol. 2012 Jun;84(6):947-956. doi: 10.1002/jmv.23282.
Roura E, Iftner T, Vidart JA, Krüger Kjaer S, Bosch FX, Muñoz N, Palacios S, San Martin Rodriguez M, Morillo C, Serradell L, Torcel-Pagnon L, Cortes J, Castellsagué X, Study Group CS. Predictors of human papillomavirus infection in women undergoing routine cervical cancer screening in Spain: the CLEOPATRE study. BMC Infect Dis. 2012 Jun 26;12(1):145.
Kahesa , Kjaer SK, Mwaiselage J, Ngoma T, Tersbol B, Dartell M and Rasch V Risk factors for VIA positivity and determinants of screening attendances in Dar es Salaam, Tanzania. BMC Public Health 2012 Dec 7;12(1):1055
Moscicki AB, Schiffman M, Burchell A, Albero G, Giuliano AR, Goodman MT, Kjaer SK, Palefsky J. Updating the natural history of human papillomavirus and anogenital cancers. Vaccine. 2012 Nov 20;30 Suppl 5:F24-33. Doi
Ruiz AM, Ruiz JE, Gavilanes AV, Eriksson T, Lehtinen M, Pérez G, Sings HL, James MK, Haupt RM; for the FUTURE I and II Study Group Proximity of First Sexual Intercourse to Menarche and Risk of High-Grade Cervical Disease. J Infect Dis. 2012 Dec;206(12):1887-1896. Epub 2012 Oct 12.
Schenker A, Straub E, Iftner T, Stubenrauch F. Cell-type dependent activities of regulatory regions and E2 proteins derived from carcinogenic and non-carcinogenic α-Human Papillomaviruses. J Gen Virol. 2013 Jun;94(Pt 6):1343-50. doi: 10.1099/vir.0.049072-0. Epub 2013 Feb 13.


MERMAID I - -
Jones, C., Khalique, L., Hogdall, E.V., Hogdall, C.K., Jacobs, I., Kruger Kjaer, S., Gayther, S.A. Array Pipeline: A dedicated Laboratory Information Management System and associated software utilities for CGH-microarray manufacture and analysis. Eur J Med Genet 2005 48:472-3 (Project 4)
J. Beesley, S.J. Jordan, A. B. Spurdle, Australian Ovarian Cancer Study Group, Australian Cancer Study (Ovarian Cancer), J. L. Hopper, H. Song, S.J. Ramus, S. Kruger Kjaer, E. Hogdall, R. A. DiCioccio, A. S. Whittemore, Simon A. Gayther, Paul D.P. Pharoah, P.M. Webb and G. Chenevix-Trench Association between SNPs in hormone metabolism and DNA repair genes and epithelial ovarian cancer: results from two Australian studies and an additional validation set. Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2557-65. (Project 1)
Høgdall EV, Christensen L, Kjaer SK, Blaakaer J, Christensen IJ, Gayther S, Jacobs IJ, Høgdall CK Expression level of Wilms tumor 1 (WT1) protein has limited prognostic value in epithelial ovarian cancer From the Danish "MALOVA" Ovarian Cancer Study. Gynecol Oncol. 2007 106:318-24 (Project 5)
Høgdall EV, Christensen L, Høgdall CK, Blaakaer J, Gayther S, Jacobs IJ, Christensen IJ, Kjaer SK. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study. Oncol Rep. 2007 Nov;18(5):1051-9.(Project 5)
Gayther SA, Song H, Ramus SJ, Kjaer SK, Whittemore AS, Quaye L, Tyrer J, Shadforth D, Hogdall E, Hogdall C, Blaeker J, DiCioccio R, McGuire V, Webb PM, Beesley J, Green AC, Whiteman DC; Australian Ovarian Cancer Study Group, Goodman MT, Lurie G, Carney ME, Modugno F, Ness RB, Edwards RP, Moysich KB, Goode EL, Couch FJ, Cunningham JM, Sellers TA, Wu AH, Pike MC, Iversen ES, Marks JR, Garcia-Closas M, Brinton L, Lissowska J, Peplonska B, Easton DF, Jacobs I, Ponder BA, Schildkraut J, Pearce CL, Chenevix-Trench G, Berchuck A, Pharoah PD; Ovarian Cancer Association Consortium. Tagging Single Nucleotide Polymorphisms In Cell Cycle Control Genes And Susceptibility To Invasive Epithelial Ovarian Cancer Cancer Res 2007 67:3027-3035 (Project 1)
Song H, Ramus SJ, Kjaer SK, Hogdall E, Dicioccio RA, Whittemore AS, McGuire V, Hogdall C, Jacobs IJ, Easton DF, Ponder BA, Dunning AM, Gayther SA, D P Pharoah P. Tagging Single Nucleotide Polymorphisms In The BRIP Gene And Susceptibility To Breast And Ovarian Cancer. PLoS ONE. 2007 7;2:e268. (Project 1)
Hogdall EV, Christensen L, Kjaer SK, Blaakaer J, Kjaerbye-Thygesen A, Gayther S, Jacobs IJ, Hogdall CK. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study. Gynaecologic Oncology 2007 104:508-515 (Project 5)
Kjærbye-Thygesen A, Huusom LD, Frederiksen K. Kjaer SK. Primary ovarian cancer. A comparison of registrations in the Danish Cancer Registry and in the Pathology Data Bank. Ugeskr Laeger. 2007 Jan 1;169(1):50-4.
Soegaard M, Jensen A, Høgdall E, Christensen L, Høgdall C, Blaakaer J, Kjaer SK. Different risk factor profiles for mucinous and nonmucinous ovarian cancer: results from the Danish MALOVA study Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1160-6
Jensen KE, Hannibal CG, Nielsen A, Jensen A, Nøhr B, Munk C, Kjaer SK. Social inequality and incidence of and survival from cancer of the female genital organs in a population-based study in Denmark, 1994-2003. Eur J Cancer. 2008 Sep;44(14):2003-17. Epub 2008 Jul 26. (related paper)
Palmieri RT, Wilson MA, Iversen ES, Clyde MA, Calingaert B, Moorman PG, Poole CL, Berchuck A, Anderson AR, Anderson S, Anton-Culver H, Australian Cancer Study (Ovarian Cancer Group), Australian Ovarian Cancer Study Group,, Beesley J, Blaaker J, Brewster W, Carney ME, Chen X, Chenvix-Trench G, Chang-Claude J, Cunningham JM, DiCioccio RA, Doherty JA, Easton DF, Edlund CK, Gayther SA, Gentry-Maharaj A, Goode EL, Goodman MT, Hogdall CK, Hogdall E, Hopkins MP, Jenison EL, Kruger Kjaer S, Lurie G, McGuire V, Menon U, Moysich KB, Ness RB, Pearce CL, Pharoah PDP, Pike MC, Ramus SJ, Rossing MA, Song H, Terada KY, Van Den Berg D, Vierkant RA, Wang-Gohrke S, Webb PM, Whittemore AS, Wu AH, Ziogas A, Schildkraut JM, on behalf of the Ovarian Cancer Association Consortium. Polymorphism in the IL18 gene and no risk of epithelial ovarian cancer in non-Hispanic white women. Cancer Epidemiol Biomarkers Prev. 2008 17:3567-3572 (Project 1)
Begum FD, Høgdall CK, Kjaer SK, Blaakaer J, Christensen L, Ryan A, Jacobs IJ, Høgdall EV. Distribution of microsatellite instability in Danish ovarian tumor patients and the prognostic value in ovarian cancer patients Oncol Res. 2008;17(1): 43-9 (Project 5)
Quaye L, Gayther SA, Ramus SJ, DiCioccio RA, McGuire V, Hogdall E, Hogdall C, Blaakær J, Easton DF, Ponder BAJ, Jacobs IJ, Kruger Kjaer S, Whittemore AS, Pearce CL, Pharoah PDP, Song H. The Effects Of Common Genetic Variants In Oncogenes On Ovarian Cancer Survival. Clin. Cancer Res. 2008 14:5833-5839 (Project 1)
Mann A, Hogdall E, Ramus SJ, Dicioccio RA, Hogdall C, Quaye L, McGuire V, Whittemore AS, Shah M, Greenberg D, Easton DF, Ponder BA, Kjaer SK, Gayther SA, Thompson DJ, Pharoah PD, Song H. Mismatch repair gene polymorphisms and survival in invasive ovarian cancer patients. Eur J Cancer. 2008 Aug 22. [Epub ahead of print] (Project 1)
Høgdall EV, Christensen L, Kjaer SK, Blaakaer J, Jarle Christensen I, Gayther S, Jacobs IJ, Høgdall CK. Protein expression levels of carcinoembryonic antigen (CEA) in Danish ovarian cancer patients: from the Danish 'MALOVA'ovarian cancer study. Pathology. 2008 Aug;40(5):487-92. (Project 5)
Ghoussaini M, Song H, Koessler T, Al Olama AA, Kote-Jarai Z, Driver KE, Pooley KA, Ramus SJ, Kjaer SK, Hogdall E, DiCioccio RA, Whittemore AS, Gayther SA, Giles GG, Guy M, Edwards SM, Morrison J, Donovan JL, Hamdy FC, Dearnaley DP, Ardern-Jones AT, Hall AL, O'Brien LT, Gehr-Swain BN, Wilkinson RA, Brown PM, Hopper JL, Neal DE, Pharoah PD, Ponder BA, Eeles RA, Easton DF, Dunning AM; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators. Multiple loci with different cancer specificities within the 8q24 gene desert. J Natl Cancer Inst. 2008 Jul 2;100(13):962-6. Epub 2008 Jun 24. (Project 1)
Soegaard M, Kjaer SK, Cox M, Wozniak E, Høgdall E, Høgdall C, Blaakaer J, Jacobs IJ, Gayther SA, Ramus SJ. BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark. Clin Cancer Res. 2008 Jun 15;14(12):3761-7. (Project 2
Høgdall V, Christensen L, Høgdall CK, Frederiksen K, Gayther S, Blaakaer J, Jacobs IJ, Kjaer SK. Distribution of p53 expression in tissue from 774 Danish ovarian tumour patients and its prognostic significance in ovarian carcinomas. APMIS. 2008 May;116(5):400-9. (Project 5)
Soegaard M, Jensen A, Frederiksen K, Høgdall E, Høgdall C, Blaakaer J, Kjaer SK. Accuracy of self-reported family history of cancer in a large case-control study of ovarian cancer. Cancer Causes Control. 2008 Jun;19(5):469-79. (Project 2)
Ramus SJ, Vierkant RA, Johnatty SE, Pike MC, Van Den Berg DJ, Wu AH, Pearce CL, Menon U, Gentry-Maharaj A, Gayther SA, Dicioccio RA, McGuire V, Whittemore AS, Song H, Easton DF, Pharoah PD, Garcia-Closas M, Chanock S, Lissowska J, Brinton L, Terry KL, Cramer DW, Tworoger SS, Hankinson SE, Berchuck A, Moorman PG, Schildkraut JM, Cunningham JM, Liebow M, Kjaer SK, Hogdall E, Hogdall C, Blaakaer J, Ness RB, Moysich KB, Edwards RP, Carney ME, Lurie G, Goodman MT, Wang-Gohrke S, Kropp S, Chang-Claude J; Australian Ovarian Cancer Study Group; Australian Cancer Study (Ovarian Cancer), Webb PM, Chen X, Beesley J, Chenevix-Trench G, Goode EL; Ovarian Cancer Association Consortium. Consortiu m analysis of 7 candidate SNPs for ovarian cancer Int J Cancer. 2008 Jul 15;123(2):380-8. (Project 1)
Morris JA, Gayther SA, Jacobs IJ, Jones C. A suite of Perl modules for handling microarray data. Bioinformatics. 2008 Apr 15;24(8):1102-3.. (Project 4)
Morris, J., Jacobs, I., Gayther, S.A. and Jones, C. A Perl toolkit for LIMS development. Source Code Biol Med. 2008 Mar 19;3:4. (Project 4)
Pearce CL, Wu AH, Gayther SA, Bale AE; Australian Cancer Study (Ovarian Cancer) and Australian Cancer Study Group, Beck PA, Beesley J, Chanock S, Cramer DW, DiCioccio R, Edwards R, Fredericksen ZS, Garcia-Closas M, Goode EL, Green AC, Hartmann LC, Hogdall E, Kjaer SK, Lissowska J, McGuire V, Modugno F, Moysich K, Ness RB, Ramus SJ, Risch HA, Sellers TA, Song H, Stram DO, Terry KL, Webb PM, Whiteman DC, Whittemore AS, Zheng W, Pharoah PD, Chenevix-Trench G, Pike MC, Schildkraut J, Berchuck A; Ovarian Cancer Association Consortium. Progesterone Receptor Variation and Risk of Invasive Epithelial Ovarian Cancer: Results from the Ovarian Cancer Association Consortium Pooled Analysis. Br J Cancer. 2008 Jan 29;98(2):282-8. (Project 1)
Song H, Hogdall E, Ramus SJ, Dicioccio RA, Hogdall C, Quaye L, McGuire V, Whittemore AS, Shah M, Greenberg D, Easton DF, Kjaer SK, Pharoah PD, Gayther SA.. Effects of common germline genetic variation in cell cycle genes on ovarian cancer survival. Clin Cancer Res. 2008 Feb 15;14(4):1090-5. (Project 1)
Cunningham JM, Vierkant RA, Sellers TA, Phelan C, Rider DN, Liebow M, Schildkraut J, Couch FJ, Wang X, Fridley BL, Gayther SA, Song H, Hogdall E, Kjaer SK, Whittemore A, DiCioccio R, Ramus SJ, Pharaoh PDP, Goode EL. Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis. B J Cancer 2009 Oct 20;101(8):1461-8. Epub 2009 Sep 8. (Project 1)
Song H, Ramus SJ, Tyrer J, Bolton K, Gentry-Maharaj A, Wozniak E, Anton-Culver H, Chang-Claude J, Cramer DW, DiCioccio R, Dörk T, Goode EL, Goodman MT, Schildkraut JM, Sellers T, Baglietto L, Beckmann MW, Beesley J, Blaakaer J, Carney ME, Chanock S, Chen Z, Cunningham JM, Dicks E, Doherty JA, Duerst M, Ekici AB, Fenstermacher D, Fridley BL, Giles G, Gore ME, De Vivo I, Hillemanns P, Hogdall C, Hogdall E, Iversen ES, Jacobs IJ, Jakubowska A, Li D, Lissowska J, Lubiński J, Lurie G, McGuire V, McLaughlin J, Mędrek K, Moorman PG, Moysich K, Narod S, Phelan C, Pye C, Risch H, Runnebaum IB, Severi G, Southey M, Stram DO, Thiel FC, Terry KL, Tsai Y, Tworoger SS, Van Den Berg DJ, Vierkant RA, Wang-Gohrke S, Webb PM, Wilkens LR, Wu AH, Yang H, Brewster W, Ziogas A, Australian Cancer (Ovarian) Study, The Australian Ovarian Cancer Study Group, The Ovarian Cancer Association Consortium, Houlston R, Tomlinson I, Whittemore AS, Rossing MA, Ponder BAJ, Pearce CL, Ness RB, Menon U, Krüger Kjaer S, Gronwald J, Garcia-Closas M, Fasching PA, Easton DF, Chenevix-Trench G, Berchuck A, Pharoah PDP and Gayther SA. Genome-Wide Association Study Identifies A Novel Ovarian Cancer Susceptibility Locus On 9p22.2 Nat. Genetics 2009 41:996-1000 (Project 1)
Quaye L, Tyrer J, Ramus SJ, Song H, Wozniak E, DiCioccio RA, McGuire V, Høgdall E, Høgdall C, Blaakaer J, Easton DF, Ponder BAJ, Krüger-Kjaer S, Whittemore AS, Gayther SA, Pharoah PDP PDP Association between Common Germline Genetic Variation in 94 Candidate Genes or regions and Risks of Invasive Epithelial Ovarian Cancer PLoS One 2009 Jun 19;4(6):e5983 (Project 1)
Song H, Ramus SJ, Krüger Kjaer S, DiCioccio RA, Chenevix-Trench G, Pearce CL, Hogdall E, Whittemore AS, McGuire V, Hogdall C, Blaakaer J, Wu AH, Menon U, Gentry-Maharaj A, Jacobs IJ, Webb PM, Beesley J, Chen X, the Australian Cancer (Ovarian) Study, The Australian Ovarian Cancer Study Group, Rossing MA, Doherty JA, Chang-Claude J, Wang-Gohrke S, Goodman MT, Lurie G, PJ, and Carney ME, Ness RB, Moysich K, Goode EL, Vierkant RA, Cunningham JM, Anderson S, Schildkraut JM, Berchuck A, Iversen ES , Moorman, Garcia-Closas M, Chanock S, Lissowska J, Brinton L, Anton-Culver H, Ziogas A, Brewster WR, Ponder BAJ, Easton DF, Gayther SA and Pharoah PDP on behalf of the Ovarian Cancer Association Consortium (OCAC). Association between invasive ovarian cancer and 11 top hits from breast cancer genome-wide association study. Hum Mol Genet. 2009 18:2297-304 (Project 1)
Schildkraut JM, Goode EL, Clyde MA, Iversen ES, Moorman PG, Berchuck A, Marks JR, Lissowska J, Brinton L, Peplonska B, Cunningham JM, Vierkant RA, Rider DN, Chenevix-Trench G, Webb PM, Beesley J, Chen X, Phelan C, Sutphen R, Sellers TA, Pearce L, Wu AH, Van Den Berg D, Conti D, Elund CK, Anderson R, Goodman MT, Lurie G, Carney ME, Thompson PJ, Gayther SA, Ramus SJ, Jacobs I, Krüger Kjaer S, Hogdall E, Blaakaer J, Hogdall C, Easton DF, Song H, Pharoah PD, Whittemore AS, McGuire V, Quaye L, Anton-Culver H, Ziogas A, Terry KL, Cramer DW, Hankinson SE, Tworoger SS, Calingaert B, Chanock S, Sherman M, Garcia-Closas M; Australian Ovarian Cancer Study Group Single Nucleotide Polymorphisms in the TP53 Region and Susceptibility to Invasive Epithelial Ovarian Cancer Cancer Res. 2009 69:2349-57 (Project 1)
Goode EL, Fridley BL, Vierkant RA, Cunningham JM, Phelan CM, Anderson S, Rider DN, Pankratz VS, Song H, Hogdall E, Kruger Kjaer S, Whittemore AS, DiCioccio R, Ramus SJ, Gayther SA, Schildkraut JM, Pharaoh PDP, and Sellers TA Candidate Gene Analysis Using Imputed Genotypes: Cell Cycle Genes and Ovarian Cancer Risk Cancer Epidemiol Biomarkers Prev. 2009 18(3):935-44. (Project 1)
Pearce CL, Near AM, Van Den Berg DJ, Ramus SJ, Gentry-Maharaj A, Menon U, Gayther SA, Anderson AR, Edlund CK, Wu AH, Chen X, Beesley J, Webb PM, Holt SK, Chen C, Doherty JA, Rossing MA, Whittemore AS, McGuire V, Dicioccio RA, Goodman MT, Lurie G, Carney ME, Wilkens LR, Ness RB, Moysich KB, Edwards R, Jennison E, Kjaer SK, Hogdall E, Hogdall CK, Goode EL, Sellers TA, Vierkant RA, Cunningham JC, Schildkraut JM, Berchuck A, Moorman PG, Iversen ES, Cramer DW, Terry KL, Vitonis AF, Titus-Ernstoff L, Song H, Pharoah PD, Spurdle AB, Anton-Culver H, Ziogas A, Brewster W, Galitovskiy V, Chenevix-Trench G; Australian Cancer Study (Ovarian Cancer); Australian Ovarian Cancer Study Group. A SNP in CYP3A4 is Associated with Genetic Susceptibility to Ovarian Cancer Br J Cancer 2009100(2):412-20 (Project 1)
Søgaard M, Frederiksen K, Jensen A, Hogdall E, Hogdall C, Blaakær J, Ramus, S, Gayther S. Risk of ovarian cancer in relation to cancer history in first degree relatives. Acta Obstet Gynecol Scand 2009 88:449-56 (Project 2)
Høgdall E, Ringsholt M, Høgdall CK, IJ Christense, Johansen JS, Kjaer SK, Blaakaer J, Ostenfeld-Møller L, Price PA, Christensen LH. YKL-40 tissue expression and plasma levels in patients with ovarian cancer. BMC Cancer. 2009 Jan; 9; 9:8 (Project 5)
Begum FD, Høgdall E, Kjaer SK, Blaakaer J, Christensen IJ, Christensen L, Høgdall C. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors. Gynecol Oncol 2009 May; 113 (2):221-7. (Project 5
Dafou D, Ramus SJ, Choi K, Grun B, Trott DA, Newbold RF, Jacobs IJ, Jones C, Gayther SA. Neoplastic Suppression in Epithelial Ovarian Cancer Cells Lines by Microcell-mediated transfer of chromosomes 6 and 18. Int J Cancer 2009 124:1037-44 (Project 3 and 5)
Quaye L, Song, H, Ramus SJ, Pearce CL, Gentry-Maharaj A, Hogdall E, DiCioccio RA, Wu A, McGuire V, Hogdall C, Jacobs IJ, Easton DF, Ponder BAJ, Whittemore AS, Kruger Kjaer S, Menon U, Pharoah PDP, Gayther SA. Tagging Single Nucleotide Polymorphisms In Candidate Oncogenes And Susceptibility To Ovarian Cancer. Br J Cancer 2009 100:993-1001 (Project 1)
Petri AL, Kjaer SK, Christensen IJ, Blaakaer J, Hogdall E, Jeppesen U, Mosgaard BJ, Pagel JD, Stilling L, Thranov I, Hogdall C Validation of epithelial ovarian cancer and fallopian tube cancer and ovarian borderline tumor data in the Danish Gynecological Cancer Database. Acta Obstet Gynecol Scand. 2009;88(5):536-42.
Petri AL, Simonsen AH, Yip TT, Hogdall E, Fung ET, Lundvall L, Hogdall C.. Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology. Acta Obstet Gynecol Scand. 2009;88(1):18-26.
Jensen A, Sharif H, Frederiksen K, Kjaer SK. Use of fertility drugs and risk of ovarian cancer: Danish Population Based Cohort Study. BMJ. 2009 Feb 5;338:b249.
West-Nørager M, Bro R, Marini F, Høgdall EV, Høgdall CK, Nedergaard L, Heegaard NH. Feasibility of serodiagnosis of ovarian cancer by mass spectrometry. Anal Chem. 2009 Mar 1;81(5):1907-13.
Jochumsen KM, Tan Q, Høgdall EV, Høgdall C, Kjaer SK, Blaakaer J, Kruse TA, Mogensen O Gene expression profiles as prognostic markers in women with ovarian cancer. Int J Gynecol Cancer. 2009 Oct;19(7):1205-13.
Sparholt MH, Høgdall E, Høgdall CK Tumour markers in epithelial ovarian cancer] Ugeskr Laeger. 2009 Nov 23;171(48):3505-9.
Risum S, Høgdall E, Engelholm SA, Fung E, Lomas L, Yip C, Petri AL, Nedergaard L, Lundvall L, Høgdall C. A proteomics panel for predicting optimal primary cytoreduction in stage III/IV ovarian cancer. Int J Gynecol Cancer. 2009 Dec;19(9):1535-8.
Petri AL, Simonsen A, Høgdall E, Christensen IJ, Krüger Kjaer S, Yip C, Risum S, Pedersen AT, Hartwell D, Fung ET, Høgdall C. Comparison of proteomic biomarker panels in urine and serum for ovarian cancer diagnosis. Proteomics Clin. Appl. 2010, 4, 304–314
Begum FD, Høgdall EV, Jarle IC, Kjaer SK, Blaakær J, Christensen L, Høgdall C Serum tetranectin as a preoperative indicator for postoperative complications in Danish ovarian cancer patients Gynecol Oncol. 2010 Jun;117(3):446-50
Pearce CL, Templeman C, Rossing MA, Lee A, Near A, Australian Cancer Study (Ovarian Cancer) , Australian Ovarian Cancer Study Group, Doherty JA, Cushing-Haugen KL, Wicklund KG, Chang-Claude J, Hein R, Wang-Gohrke S, Lurie G, Wilkens LR, Carney ME, Goodman MT, Moysich K,. Kjaer SK, Hogdall E, Jensen A, Goode EL, Fridley BL, Larson MC, Schildkraut JM, Palmieri RT, Cramer DW, Terry KL, Vitonis AF, Titus-Ernstoff L, Ziogas A, Brewster W, Anton-Culver H, Gentry Maharaj A, Ramus SJ, Anderson R, Brueggmann D, Fasching PA, Gayther SA, Huntsman D, Menon U, Nagle5 CM, Ness R, PikeMC, Risch H, Webb PM, Wu AH, Berchuck A on behalf of the Ovarian Cancer Association Consortium. (Ingen titel på emne) JNCI (submitted Nov 20, 2010) (Project 1)
Amankwah EK, Wang Q, Schildkraut JM, Tsai Y, Ramus SJ, Fridley BL, Beesley J, Johnatty SE, Webb PM, Chenevix-Trench G, Australian Ovarian Cancer Study Group, Dale LC, Lambrechts D, Amant F, Despierre E, Vergote I, Gayther SA, Gentry-Maharaj A, Menon U, Chang-Claude J, Wang-Gohrke S, Anton-Culver H, Ziogas A, Doerk T, Duerst M, Antonenkova N, Bogdanova N,15, Brown R, Flanagan JM, Kaye SB, Paul J, Bützow R, Nevanlinna H, Campbell I, Eccles DM, Karlan BY, Gross J, Walsh C, Pharoah P, Song H, Kjær SK, Høgdall E, Høgdall C, Lundvall L, Nedergaard L, Kiemeney L, Massuger L, van Altena AM, Vermeulen S, Le ND, Brooks-Wilson A, Cook LS, Phelan CM, Cunningham JM, Vachon CM, Vierkant RA, Iversen ES, Berchuck A, Goode EL, Sellers TA and Kelemen LE on behalf of the Ovarian Cancer Association Consortium. Pearce CL, Ramus SJ, Jacobs IJ, Gayther SA. Polymorphisms in stromal genes decorin and lumican and susceptibility to serous ovarian cancer: a report from the Ovarian Cancer Association Consortium. PLoS One2010 (submitted Nov. 2010) (Project 1)
Ramus, S, Quaye L, Wosniak E, Høgdall E, Høgdall C, Blaakær J, Kruger Kjaer S, Jacobs I, Gayther S. Evaluating Whole Genome Amplification Methods and Multiplex SNP Genotyping Platforms for Genetic Association Studies. PlosONE 2010 (submitted April) (Project 1)
Dafou D, Grun B, Sinclair J, Lawrenson K, Benjamin EC, Hogdall E, Kruger-Kjaer S, Christensen L, Sowter HM, Al-Attar A, Edmondson R, Darby S, Berchuck A, Laird PW, Microcell-mediated chromosome transfer identifies EPB41L3 as a functional suppressor of epithelial ovarian cancers. Neoplasia. 2010 Jul;12(7):579-89. (Project 1)
Kelemen LE, Goodman MT, McGuire V, Rossing MA, Webb PM; Australian Cancer Study (Ovarian Cancer) Study Group, Köbel M, Anton-Culver H, Beesley J, Berchuck A, Brar S, Carney ME, Chang-Claude J, Chenevix-Trench G; Australian Ovarian Cancer Study Group, Cramer DW, Cunningham JM, Dicioccio RA, Doherty JA, Easton DF, Fredericksen ZS, Fridley BL, Gates MA, Gayther SA, Gentry-Maharaj A, Høgdall E, Kjaer SK, Lurie G, Menon U, Moorman PG, Moysich K, Ness RB, Palmieri RT, Pearce CL, Pharoah PD, Ramus SJ, Song H, Stram DO, Tworoger SS, Van Den Berg D, Vierkant RA, Wang-Gohrke S, Whittemore AS, Wilkens LR, Wu AH, Schildkraut JM, Sellers TA, Goode EL; Ovarian Cancer Association Consortium Genetic variation in TYMS in the one-carbon transfer pathway is associated with ovarian carcinoma types in the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev. 2010 Jul;19(7):1822-30. Epub 2010 Jun 22. (Project 1)
Høgdall EV, Christensen L, Kjaer SK, Blaakaer J, Christensen IJ, Høgdall CK Limited prognostic value of tissue protein expression levels of BCl-2 in Danish ovarian cancer patients: from the Danish 'MALOVA' ovarian cancer study. APMIS. 2010 Aug;118(8):557-64. (Project 5)
Near AM, Wu AH, Templeman C, Van Den Berg DJ, Doherty JA, Rossing MA, Goode EL, Cunningham JM, Vierkant RA, Fridley BL, Chenevix-Trench G, Webb PM; the Australian Cancer Study (Ovarian Cancer) (ACS).,; the Australian Ovarian Cancer Study Group (AOCS), Kjær SK, Hogdall E, Gayther SA, Ramus SJ, Menon U, Gentry-Maharaj A, Schildkraut JM, Moorman PG, Palmieri RT, Ness RB, Moysich K, Cramer DW, Terry KL, Vitonis AF, Pike MC, Berchuck A, Pearce CL; on behalf of the Ovarian Cancer Association Consortium. Progesterone receptor gene polymorphisms and risk of endometriosis: results from an international collaborative effort. Fertil Steril. 2010 Aug 16. [Epub ahead of print] (project 1)
Johnatty SE, Beesley J, Chen X, Duffy D, Spurdle AB, DeFazio A, Gava N, Webb PM, Australian Ovarian Cancer Study Group, Australian Cancer Study (Ovarian Cancer), Rossing MA, Chang Claude J, Goodman M, Ness R, Cramer D, Hankinson S, Garcia-Closas M, Pharoah P, Whitemore A, Pearce CL, Gayther SA, Anton-Culver H, Hogdal E, Berchuck A, Ramus SJ, Menon U, Gentry-Maharaj A, Rider DN, Goode EL, Haviv I, Chenevix-Trench G on behalf of the Ovarian Cancer Association Consortium. Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility “hot-spot”. PLoS Genet. 2010 Jul 8;6(7):e1001016 (Project 1)
Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, Sher T, Gentry-Maharaj A, Wozniak E, Tsai YY, Weidhaas J, Paik D, Van Den Berg DJ, Stram DO, Pearce CL, Wu AH, Brewster W, Anton-Culver H, Ziogas A, Narod SA, Levine DA, Kaye SB, Brown R, Paul J, Flanagan J, Sieh W, McGuire V, Whittemore AS, Campbell I, Gore ME, Lissowska J, Yang HP, Medrek K, Gronwald J, Lubinski J, Jakubowska A, Le ND, Cook LS, Kelemen LE, Brook-Wilson A, Massuger LF, Kiemeney LA, Aben KK, van Altena AM, Houlston R, Tomlinson I, Palmieri RT, Moorman PG, Schildkraut J, Iversen ES, Phelan C, Vierkant RA, Cunningham JM, Goode EL, Fridley BL, Kruger-Kjaer S, Blaeker J, Hogdall E, Hogdall C, Gross J, Karlan BY, Ness RB, Edwards RP, Odunsi K, Moyisch KB, Baker JA, Modugno F, Heikkinenen T, Butzow R, Nevanlinna H, Leminen A, Bogdanova N, Antonenkova N, Doerk T, Hillemanns P, Dürst M, Runnebaum I, Thompson PJ, Carney ME, Goodman MT, Lurie G, Wang-Gohrke S, Hein R, Chang-Claude J, Rossing MA, Cushing-Haugen KL, Doherty J, Chen C, Rafnar T, Besenbacher S, Sulem P, Stefansson K, Birrer MJ, Terry KL, Hernandez D, Cramer DW, Vergote I, Amant F, Lambrechts D, Despierre, Ekici AB, Chen X; the Australian Ovarian Cancer Study Group; the Australian Cancer Study (Ovarian Cancer); on behalf of the Ovarian Cancer Association Consortium, Johnatty SE, Webb PM, Beesley J, Chanock S, Garcia-Closas M, Sellers T, Easton DF, Berchuck A, Chenevix-Trench G, Pharoah PD, Gayther SA. E, Fasching PA, Beckmann MW, Thiel FC, Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet. 2010 42, 880-884 (Project 1)
Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, Lawrenson K, Widschwendter M, Vierkant RA, Larson MC, Kjaer SK, Birrer MJ, Berchuck A, Schildkraut J, Tomlinson I, Kiemeney LA, Cook LS, Gronwald J, Garcia-Closas M, Gore ME, Campbell I, Whittemore AS, Sutphen R, Phelan C, Anton-Culver H, Pearce CL, Lambrechts D, Rossing MA, Chang-Claude J, Moysich KB, Goodman MT, Dörk T, Nevanlinna H, Ness RB, Rafnar T, Hogdall C, Hogdall E, Fridley BL, Cunningham JM, Sieh W, McGuire V, Godwin AK, Cramer DW, Hernandez D, Levine D, Lu K, Iversen ES, Palmieri RT, Houlston R, van Altena AM, Aben KK, Massuger LF, Brooks-Wilson A, Kelemen LE, Le ND, Jakubowska A, Lubinski J, Medrek K, Stafford A, Easton DF, Tyrer J, Bolton KL, Harrington P, Eccles D, Chen A, Molina AN, Davila BN, Arango H, Tsai YY, Chen Z, Risch HA, McLaughlin J, Narod SA, Ziogas A, Brewster W, Gentry-Maharaj A, Menon U, Wu AH, Stram DO, Pike MC; The Wellcome Trust Case-Control Consortium, Beesley J, Webb PM; The Australian Cancer Study (Ovarian Cancer); The Australian Ovarian Cancer Study Group; the Ovarian Cancer Association Consortium (OCAC), Chen X, Ekici, Wentzensen N, Lissowska J, Fasching PA, Despierre E, Amant F, Vergote I, Doherty J, Hein R, Wang-Gohrke S, Lurie G, Carney ME, Thompson PJ, Runnebaum I, Hillemanns P, Dürst M, Antonenkova N, Bogdanova N, Leminen A, Butzow R, Heikkinen T, Stefansson K, Sulem P, Besenbacher S, Sellers TA, Gayther SA, Pharoah PD. AB, Thiel FC, Beckmann MW, Yang H, A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24 Nat Genet. 2010 Nat Genet. 2010 42, 874-879 (Project 1)
Notaridou M, Quaye L, Dafou D, Jones C, Song H, Høgdall E, Kjaer SK, Christensen L, Høgdall C, Blaakaer J, McGuire V, Wu AH, Van Den Berg DJ, Pike MC, Gentry-Maharaj A, Wozniak E, Sher T, Jacobs IJ, Tyrer J, Schildkraut JM, Moorman PG, Iversen ES, Jakubowska A, Medrek K, Lubiński J, Ness RB, Moysich KB, Lurie G, Wilkens LR, Carney ME, Wang-Gohrke S, Doherty JA, Rossing MA, Beckmann MW, Thiel FC, Ekici AB, Chen X, Beesley J, Gronwald J, Fasching PA, Chang-Claude J, Goodman MT, Chenevix-Trench G, Berchuck A, Pearce CL, Whittemore AS, Menon U, Pharoah PD, Gayther SA, Ramus SJ; The Australian Ovarian Cancer Study Group/Australian Cancer Study (Ovarian Cancer); on behalf of the Ovarian Cancer Association Consortium. Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer Int J Cancer. 2010 Jul 15. [Epub ahead of print] (Project 1)
Phelan CM, Tsai1 YY, Goode EL, Cunningham JM, Fredericksen ZS, Australian Cancer Study (Ovarian Cancer) and Australian Ovarian Cancer Study Group, Beesley J, Chen X, Webb PM, Chanock S, Cramer DW, Moysich K, Edwards RP, Chang-Claude J, Garcia-Closas M, Yang H, Wang-Gohrke S, Kropp S, Green AC, Hartmann LC, Couch F, Vierkant RA, Lissowska J, Carney ME, Lurie G, Wilkens LR, Modugno F, Ness RB, Pearce CL, Wu AH, Van Den Berg DJ, Stram DO, Terry KL, Webb PM, Whiteman DC, Whittemore A, DiCioccio RA, McGuire V, Holt SK, Chen C, Doherty JA, Rossing MA, Anton-Culver H, Ziogas A, Hogdall C, Hogdall E, Krüger Kjaer S, Blaakaer J, Ramus SJ, Gentry-Maharaj A, Menon A, Pharoah PDP, Iversen ES, Marks JR, Pike MC, Gayther SA, Goodman MT, Schildkraut JM, Chenevix-Trench G, Berchuck A and Sellers TA on behalf of the Ovarian Cancer Association Consortium (OCAC). Polymorphisms in the GALNT1 Gene and Epithelial Ovarian Cancer Risks in Non-Hispanic White Women: the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):600-4. (Project 1)
Begum FD, Høgdall E, Christensen IJ, Kjaer SK, Blaakaer J, Christensen L, Høgdall C. Serum tetranectin is a significant prognostic marker in ovarian cancer patients. Acta Obstet Gynecol Scand 2010 Feb;89(2):190 (Project 5)
Doherty JA, Rossing MA, Cushing-Haugen KL, Chen C, Van Den Berg DJ, Wu AH, Pike MC, Ness RB, Moysich K, Chenevix-Trench G, Webb PM, Chang-Claude J, Wang-Gohrke S, Goodman MT, Lurie G, Hogdall E, Kruger Kjaer S, Goode EL, Cunningham JM, Berchuck A, Moorman PG, Schildkraut JM, Cramer DW, Terry KL, Garcia-Closas M, Lissowska J, Song H, Pharoah PDP, McGuire V, Whittemore AS, Gayther SA, Ramus SJ, Anton-Culver H, The Australian Ovarian Cancer Study Group, The Australian Cancer Study (Ovarian Cancer), Leigh Pearce CL on behalf of the Ovarian Cancer Association Consortium (OCAC). ESR1/SYNE1 polymorphism and invasive epithelial ovarian cancer risk: an Ovarian Cancer Association Consortium study. Cancer Epidemiol Biomarkers and Prevention 2010 Jan;19(1):245-50.. (Project 1)
Hogdall EV, Christensen L, Kjaer SK, Blaakaer J, Bock JE, Glud E, Norgaard-Pedersen B, Hogdall CK. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Cancer. 2003;98:66-73.
Hogdall EV, Kjaer SK, Glud E, Christensen L, Blaakaer J, Vuust J, Bock JE, Norgaard-Pedersen B, Hogdall CK. Evaluation of a polymorphism in intron 2 of the p53 gene in ovarian cancer patients. From the Danish "Malova" Ovarian Cancer Study. Anticancer Res. 2003;23:3397-404.
Hogdall EV, Johansen JS, Kjaer SK, Price PA, Christensen L, Blaakaer J, Bock JE, Glud E, Hogdall CK. High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival. Oncol Rep. 2003;10:1535-8.
Hogdall EV, Hogdall CK, Blaakaer j, Christensen L, Bock JE, Vuust J, Glud E, Kjaer SK. K-ras alterations in Danish ovarian tumour patients. From the Danish “Malova” Ovarian Cancer study. Gynecol Oncol. 2003;89:31-6.
Dehn H, Hogdall EV, Johansen JS, Jorgensen M, Price PA, Engelholm SA, Hogdall CK. Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer. Acta Obstet Gynecol Scand. 2003;82:287-93.
Brinton LA, Kjær SK, Thomsen BL, Sharif H, Graubard B, Olsen JH, Bock JE Childhood tumor risk following treatment with ovarian stimulating drugs Fertility and Sterility. 2004;81:1083-91.
Holten-Andersen MN, Schrohl AS, Brunner N, Nielsen HJ, Hogdall CK, Hogdall EV. Evaluation of sample handling in relation to levels of tissue inhibitor of metalloproteinases-1 measured in blood by immunoassay. Int J Biol Markers. 2003;18:170-6.
Gronlund B, Hansen HH, Hogdall C, Hogdall EV, Engelholm SA. Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma? Br J Cancer. 2004;90:377-82.
Glud E, Kjaer SK, Thomsen BL, Hogdall C, Christensen L, Hogdall E, Bock JE, Blaakaer J. Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. Arch Intern Med. 2004;164:2253-9.
Hogdall EV, Ryan A, Kjaer SK, Blaakaer J, Christensen L, Bock JE, Glud E, Jacobs IJ, Hogdall CK. Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma. Cancer. 2004;100:2387-95.
Gronlund B, Hogdall C, Hilden J, Engelholm SA, Hogdall EV, Hansen HH. Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma? J. Clin Oncol. 2004;22:4051-8.
Dicioccio RA, Song H, Waterfall C, Kimura MT, Nagase H, McGuire V, Høgdall E, Shah MN, Luben RN, Easton DF, Jacobs IJ, Ponder BA, Whittemore AS, Gayther SA, Pharoah PD, Kruger-Kjaer S. STK15 polymorphisms and association with risk of invasive ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2004;13:1589-94.
Begum FD, Hogdall CK, Kjaer SK, Christensen L, Blaakaer J, Bock JE, Glud E, Hoyer-Hansen G, Ring-Larsen H, Hogdall EV. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients. Anticancer Res. 2004;24:1981-5.
Pastrana DV, Buck CB, Pang Y-YS, Thompson CD, Castle PE, Kjær SK, Lowy DR, Schiller JT Reactivity of Human Sera in Sensitive High Throughput Pseudovirus Based Neutralization Assays for HPV16 and HPV18 Virology. 2004;321: 205-16.
Kjær SK, Mellemkjaer L, Brinton LA, Johansen C, Gridley G, Olsen JH Tubal sterilization and risk of ovarian, endometrial and cervical cancer. A population-based follow-up study of more than 65 000 sterilized women Int J Epidemiol 2004; 33:596-602.
Kirschner B, Simonsen K, Junge J, Kjær SK Livmoderhalskræft og human papillomavirus. Nye perspektiver inden for screening af livmoderhalskræft Månedskr Prakt Lægegern. 2005;83: 923-8.
Auranen A, Song H, Waterfall C, Dicioccio RA, Kuschel B, Kjaer SK, Høgdall E, Høgdall C, Stratton J, Whittenmore AS, Easton DF, Ponder BA, Novik KL, Dunning AM, Gayther S, Pharoah PD. Polymorphisms in DNA repair genes and epithelial ovarian cancer risk Int J Cancer. 2005 May 27;
Bøjesen SE, Kjær SK, Høgdall EV, Thomsen BL, Høgdall CK, Blåkær J, Tybjær-Hansen A, Nordestgaard BG Increased risk of ovarian Cancer in integrin beta3 Leu33Pro homozygotes Endocr Relat Cancer. 2005;12: 945-52.
Brinton LA, Sakoda LC, Sherman ME, Frederiksen K, Kjær SK, Graubard BI, Olsen JH, Mellemkjaer L Relationship of benign gynecologic diseases to subsequent risk of ovarian and uterine tumors Cancer Epidemiol, Biomarkers and Prevention. 2005;14:2929-35.
Kjærbye-Thygesen A, Huusom LD, Frederiksen K, Kjaer SK Trends in the Incidence and Mortality of Ovarian Cancer in Denmark 1978-2002. Comparison with other Nordic countries ACTA. 2005;84:1006-12.
Kjaer SK, Munk C, WintherJF, Jørgensen HO, Meijer C, van den Brule A Acquisition and persistence of HPV infection in younger men. A prospective follow-up study among Danish soldiers Cancer Epidemiol, Biomarkers and Prevention. 2005;14:1528-33.
West-Nielsen M, Høgdall EV, Marchiori E, Høgdall CK, Sshou C, Heegaard NH Sample handling for mass spectrometric proteomic investigations of human sera Anal Chem. 2005;77: 5114-23.
International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical carcinoma and reproductive factors: Collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 Int J Cancer. 2006 Mar 28; [Epub ahead of print]
Kyndi M, Frederiksen K, Kjær SK Cervical cancer incidence in Denmark over six decades (1943-2002). Acta Obstet Gynecol Scand. 2006;85:106-11.
Moscicki AB, Schiffman M, Kjaer SK, Villa, LL: Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine. 2006 Aug 21;24 Suppl 3:S42-51. Epub 2006 Jun 23.
Kjaer S, Høgdall E, Frederiksen K, Munk C, Van den Brule A, Svare E, Meijer C, Lorincz A, Iftner T. The absolute risk of cervical abnormalities in high-risk HPV positive, cytologically negative women over a 10 year period. Cancer Res. 2006 Nov 1;66(21):10630-6. Epub 2006 Oct 23.
Kjær SK, Olesen F, Toftager-Larsen K, Sand C, Strauss GI, Hoffmann TU, Ottesen BS The first HPV vaccine is now available Ugeskr Laeger. 2006;168:3827-8.
Kjær SK Vaccine against human papillomavirus Ugeskr Læg 2006;12:1218.
Tolstrup JS, Munk C, Thomsen B, Svare E, van den Brule AJC, Grønbæk M, Meijer C, Kjær SK The role of smoking and alcohol intake in the development of HSIL among high-risk HPV positive women Acta Obstet Gynecol Scand. 2006;85:1114-9.
Soegaard M, Kjaer SK, Gayther S. Ovarian cancer and genetic susceptibility in relation to the BRCA1 and BRCA2 genes. Occurrence, clinical importance and intervention. Acta Obstet Gynecol Scand. 2006:93-105.
Kjærbye-Thygesen A, Frederiksen K, Høgdall EV, Glud E, Christensen L, Høgdall CK, Blaakjaer J, Kjaer SK Smoking and overweight: negative prognostic factors in stage III epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2006;15:798-803.
Kjærbye-Thygesen A, Frederiksen K, Høgdall EV, Høgdall CK, Blaakjaer J, Kjaer SK Do risk factors for epithelial ovarian cancer have an impact on prognosis? Focus on previous pelvic surgery and reproductive variables. Eur J Gyn Oncol 2006;XXVII:467-472
Høgdall EV, Kjær SK, Blaakær J, Christensen L, Glud E, Vuust J, Høgdall C P53 mutations in tissue from Danish ovarian cancer patients: from the Danish MALOVA ovarian cancer study Gynecol. Oncol. 2006;100:76-82.
Petri AL, Høgdall E, Christensen IJ, Kjær SK, Blåkær J, Høgdall C Preoperative CA125 as a prognostic factor in stage I epithelial ovarian cancer Apmis. 2006;114: 359-63.
Song H, Ramus SJ, Quaye L, Dicioccio RA, Tyrer J, Lomas E, Shadford D, Høgdall E, McGuire V, Whittemore AS, Easton DF, Ponder BA, Kjær SK, Pharoah PD, Gayther SA. Common variants in mismatch repair genes and risk of invasive ovarian cancer Carcinogenesis 2006 Jun 13:
Huusom LD, Frederiksen K, Høgdall EV, Glud E, Christensen L, Høgdall C, Blåkær J, Kjær SK. Association of reproductive factors, oral contraceptive use and selected lifestyle factors with the risk of ovarian borderline tumors: a Danish case-control study. Cancer Causes Control. 2006;17: 821-9.
Begum FD, Høgdall EV, Riisbro R, Christensen IJ, Engelholm SA, Jørgensen M, Pedersen BN, Høgdall CK. Prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) in Danish patients with recurrent epithelial ovarian cancer (REOC) APMIS. 2006;114: 675-81.
Grønlund b, Høgdall EV, Christensen IJ, Johansen JS, Nørgård-Pedersen B, Engelholm SA, Høgdall C Pre-treatment prediction of chemorestistance in second-line chemotherapy of ovarian cancer: value of serological tumor marker determination (tetranectin, YKL-40, CASA, CA125) Int J Biol Markers. 2006;21:141-8.
Høgdall E, Christensen L, Kjær SK, Blaakær J, Kjærbye-Thygesen A, Gayther S, Jacobs IJ, Høgdall C. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumour patients. Gynecol Oncol 2006
Song H, Ramus SJ, Shadforth D, Quaye L, Kru¨ger SK, Dicioccio RA, Dunning AM, Hogdall e, Hogdall C, Whittemore A, McGuire V, Lesueur F, Easton DF, Jacobs I, Ponder BA, Gayther S, Pharoah PD. Common variants in RB1Gene and risk of invasive ovarian cancer Cancer Research. 2006;66:10220-6.
Gayther SA, Song H, Ramus SJ, Kjaer SK, Whittermore A, Quaye L,Tyre J, Shadforth D, Hogdall E, Hogdall C, Blaakaer J, DiCioccio R, McGuire V, Webb V, Beesley J, Green AD, Whiteman DC, The Australian Cancer Study (Ovarian Cancer), Goodman MT, Lurie G, Car Tagging Single Nucleotide Polymorphisms In Cell Cycle Control Genes And Susceptibility To Invasive Epithelial Ovarian Cancer. Cancer Research
Buss L, Tolstrup J, Munk C, Bergholt T , Ottesen B, Grønbæk M, Kjaer SK Spontaneous abortion – A prospective cohort study of younger women from the general population in Denmark. Validation, occurrence and risk determinants Acta Obstet Gynecol Scand. 2006;85:467-75.
Mikkel West-Nørager, Christian Dahl Kelstrup, Christian Schou, Estrid V. Høgdall, Claus K. Høgdall, Niels H. H. Heegaard Unravelling in vitro variables of major importance for the outcome of mass spectrometry-based serum proteomics Journal of chromatography B
Müller LL, Munk C, Thomsen BL, Frederiksen K, Kjaer SK The influence of parity and smoking in the social environment on tobacco consumption among 3672 daily smoking women in Denmark European Addiction Research 2006
Jacobsen R, Jacobsen R, Moller H, Thoresen SO, Pukkala E, Kjaer SK, Johansen C Trends in testicular cancer incidence in the Nordic countries, focusing on the recent decrease in Denmark Int J Androl. 2006;29:199-204.
Mellemkjær L, Hasle H, Gridley G, Johansen C, Kjær SK, Olsen JH Risk of cancer in children with the diagnosis immaturity at birth. Paediatr Perinat Epidemiol. 2006;20:231-7.
Kjærbye-Thygesen A, Kjaer SK, Frederiksen K, Høgdall EV, Høgdall CK, Christensen L, Blaakjaer J Prognostic impact of preoperative endogenous hormone status in postmenopausal women diagnosed with epithelial ovarian cancer. Focusing on Inhibin A, Estradiol and Androgens Endocr Relat Cancer
Marie Søgaard, Allan Jensen, estrid Högdall, Lise Christensen, Claus Högdall, Jan Blaakær, Susanne K. Kjaer Different risk factor profiles for mucinous and non-mucinous ovarian cancer. Results from the danish MALOVA study. In preparation.
Huusom LD, Kjærbye-Thygesen A, Frederiksen K, Kjaer SK Registration of ovarian borderline tumours in Denmark 1978-79 In preparation.
Kjærbye-Thygesen A, Huusom LD, Frederiksen K, Kjaer SK Primær ovariecancer. En sammenligning af registreringer i Cancerregisteret og Patologidatabanken. Ugeskr Laeger